var title_f14_2_14368="Pes cavus foot";
var content_f14_2_14368=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pes cavus foot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients with a high arch (pes cavus), as shown in this photograph, may be at higher risk for patellofemoral pain syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_2_14368=[""].join("\n");
var outline_f14_2_14368=null;
var title_f14_2_14369="Pediatric manual C-spine immobilization";
var content_f14_2_14369=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Manual stabilization of the pediatric spine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 465px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_2_14369=[""].join("\n");
var outline_f14_2_14369=null;
var title_f14_2_14370="Ethyl chloride: Drug information";
var content_f14_2_14370=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ethyl chloride: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gebauer's Ethyl Chloride&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F168857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F168849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Pain relief:",
"     </b>",
"     Topical: Dosage varies with use. In general, spray affected area 3-7 seconds from spray bottle (4-10 seconds from spray can) until  the tissue becomes white.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F168850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F168842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, spray, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gebauer's Ethyl Chloride&reg;: 100% (103.5 mL) [fine stream spray glass bottle]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gebauer's Ethyl Chloride&reg;: 100% (103.5 mL) [medium stream spray can]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gebauer's Ethyl Chloride&reg;: 100% (103.5 mL) [medium stream spray glass bottle]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gebauer's Ethyl Chloride&reg;: 100% (103.5 mL) [mist spray can]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F168833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F168844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For topical use only. Spray for a few seconds (in general, 3-7 seconds from spray bottle and 4-10 seconds from spray can) until the tissue becomes white; avoid prolonged spraying of skin to avoid frosting of the skin; avoid broken skin, eyes, and mucous membranes; if used for local freezing of tissues, apply petroleum to adjacent skin areas for protection.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F168843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local anesthetic in minor operative procedures; control pain associated with injections, starting I.V. lines, and venipuncture; relieve pain caused by minor sport injury, bruises, myofascial and visceral pain syndromes",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F168855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Mucous membrane irritation, freezing may alter skin pigment, sensitization (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13825321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ethyl chloride or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13825322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Systemic effects: May be absorbed through the skin; cases of chronic poisoning have not been reported. Ethyl chloride is known as a liver and kidney toxin; long-term exposure may cause damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: For topical use only. Do not spray into eyes; avoid inhalation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Flammable: Formulation is flammable; avoid use near open flame or electrical cautery equipment. Do not place on hot surfaces.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13825351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Skin absorption may occur; the amount of ethyl chloride available systemically is unknown.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F168846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aethylum Chloratum (PL);",
"     </li>",
"     <li>",
"      athylchlorid Sintetica (CH);",
"     </li>",
"     <li>",
"      Chloraethyl (DE);",
"     </li>",
"     <li>",
"      Chloraethyl Adroka (CH);",
"     </li>",
"     <li>",
"      Cloretilo Chemirosa (ES);",
"     </li>",
"     <li>",
"      Holsten aktiv (DE);",
"     </li>",
"     <li>",
"      WariActiv (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13825352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Duration: A few seconds to 1 minute",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8930 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A392849A5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_2_14370=[""].join("\n");
var outline_f14_2_14370=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168848\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168857\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168849\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168850\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168842\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168833\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168844\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168843\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168855\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825321\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825322\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299300\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220238\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825351\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168846\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825352\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8930\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8930|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_2_14371="Toe plate";
var content_f14_2_14371=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Toe platform extension of cast used in the treatment of great toe fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eiff, PE, Hatch, RL, Calmbach, WL. Fracture Management for Primary Care, 2nd ed, Saunders, New York, 2003. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_2_14371=[""].join("\n");
var outline_f14_2_14371=null;
var title_f14_2_14372="ACTH Cushings disease";
var content_f14_2_14372=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F54316&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F54316&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Pulse analysis of plasma ACTH in Cushing's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Analysis of specimens sampled at 10-minute intervals for 24 hours in normal subjects (left four panels) and patients with Cushing's disease (right four panels) reveals that in Cushing's disease, the amplitude and duration, but not the frequency of ACTH secretory episodes are increased.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: van den Berg G, Fr&ouml;lich M, Veldhuis JD, Roelfsema F. Combined amplification of the pulsatile and basal modes of adrenocorticotropin and cortisol secretion in patients with Cushing's disease: evidence for decreased responsiveness of the adrenal glands.&nbsp;J Clin Endocrinol Metab 1995; 80:3750.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_2_14372=[""].join("\n");
var outline_f14_2_14372=null;
var title_f14_2_14373="Tenaculum apple extraction";
var content_f14_2_14373=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tenaculum use for apple extraction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 389px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transanal extraction of a rectal foreign body. Note use of a Richardson retractor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott Steele, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_2_14373=[""].join("\n");
var outline_f14_2_14373=null;
var title_f14_2_14374="Cyproterone: Drug information";
var content_f14_2_14374=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cyproterone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/15/6389?source=see_link\">",
"    see \"Cyproterone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F155793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Androcur&reg;;",
"     </li>",
"     <li>",
"      Androcur&reg; Depot;",
"     </li>",
"     <li>",
"      Novo-Cyproterone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F155804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiandrogen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F155794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prostate cancer, advanced (palliative treatment):",
"     </b>",
"     Males:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 200-300 mg daily in 2-3 divided doses (maximum: 300 mg daily); following orchiectomy, reduce dose to 100-200 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 300 mg (3 mL) once weekly; reduce dose in orchiectomized patients to 300 mg every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     May interchange between oral and I.M. administration during chronic therapy; dosages should remain within usual ranges (oral: 100-300 mg daily; I.M.: 300 mg weekly or every 2 weeks).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of paraphilia/hypersexuality (unlabeled use; Guay, 2009; Reilly, 2000):",
"     </b>",
"     Males (",
"     <b>",
"      Note:",
"     </b>",
"     Avoid use if active pituitary pathology, hepatic failure, or thromboembolic disease):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 50-600 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 300-600 mg weekly or every other week",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F155795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Has not been studied in patients with renal impairment. Use with caution; 33% of cyproterone is excreted renally.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F155796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated with hepatic impairment or liver disease.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10241394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as acetate: 100 mg/mL (3 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Androcur&reg; Depot: 100 mg/mL (3 mL) [contains benzyl benzoate and castor oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, as acetate: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Androcur&reg;: 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11218428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F155778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.: Administer I.M. injections slowly and avoid intravascular injection which can lead to pulmonary microembolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer tablets at the same time each day, after meals and with liquids. Tablets may be divided into equal halves.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F155777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Palliative treatment of advanced prostate cancer",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F15070678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of paraphilia/hypersexuality",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F155802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, heart failure, hypotension, MI, phlebitis, shock, stroke, syncope, tachycardia, thrombosis (DVT, embolus, superficial venous thrombosis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Aphasia, chills, coma, depression, dizziness, encephalopathy, fatigue, headache, hemiplegia, lassitude, malaise, meningioma (with chronic therapy), personality disorder, psychotic depression, pyrexia, restlessness, vascular headache, vasovagal reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dry skin (sebum reduction), eczema, erythema nodosum, exfoliative dermatitis, hirsutism, maculopapular rash, patchy loss of body hair, photosensitivity, pruritus, rash, scleroderma, skin discoloration, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Adrenal suppression (dose related), benign nodular breast hyperplasia, diabetes mellitus, galactorrhea, gynecomastia, hot flashes, hypercalcemia, hyperglycemia, hypernatremia, impotence, inhibition of spermatogenesis, libido decreased, negative nitrogen balance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, dyspepsia, glossitis, nausea, pancreatitis, vomiting, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Bladder carcinoma, crystalluria, urinary frequency, uterine fibroids enlarged, uterine hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, fibrinogen increased, hemolytic anemia, hemorrhage, hypochromic anemia, leukopenia, leukocytosis, normocytic anemia, PT decreased, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Ascites, cholestatic jaundice, cirrhosis, hepatic carcinoma, hepatic coma, hepatic dysfunction (dose related), hepatic failure, hepatic necrosis, hepatitis, hepatoma, hepatomegaly, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular and skeletal: Gait abnormal, myasthenia, osteoporosis, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Abnormal accommodation, abnormal vision, blindness, optic neuritis, optic atrophy, retinal vascular disorder, retinal vein thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hematuria, renal failure, serum creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, cough, dyspnea, hyperventilation, pulmonary embolism, pulmonary fibrosis, pulmonary oil microembolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F155781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cyproterone or any component of the formulation; liver disease or hepatic dysfunction; Dubin-Johnson syndrome; Rotor syndrome; previous or existing liver tumors (if not due to metastases from prostate cancer); presence or history of meningioma; wasting diseases (except inoperable prostate cancer); severe chronic depression; existing thromboembolic processes",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F155767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenalcortical function suppression:  Has been reported with use; monitor adrenal function periodically during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anemia: Hypochromic anemia has been observed (rarely); monitor CBC regularly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiandrogen withdrawal syndrome: Antiandrogens may promote prostate cancer growth in some patients with metastatic prostate cancer; discontinue therapy immediately with increasing prostate specific antigen (PSA) levels and monitor 6-8 weeks for withdrawal response prior to initiating alternative treatment. Decreased PSA levels and/or clinical improvement have been reported following therapy discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carcinogenesis: Benign and malignant hepatic tumors have been observed (rarely) after use; rule out the presence of tumor in patients presenting with severe upper abdominal discomfort, hepatic enlargement or signs of intra-abdominal hemorrhage. Meningioma formation has been reported with chronic therapy (years) at doses &ge;25 mg/day. Avoid initiation of therapy in patients with a history or presence of meningioma; discontinue treatment in patients diagnosed with meningioma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: Lassitude, weakness, and fatigue are common during first few weeks of treatment; symptoms usually lessen ~3 months after therapy initiation. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gynecomastia: Hyperplasia of the breast has been reported; subsides usually within 1-3 months after therapy discontinuation and/or dose reduction. Risk of treatment failure should be considered prior to discontinuation or dose reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [Canadian Boxed Warning]:",
"     </b>",
"     Use  is associated with dose-dependent hepatotoxicity (jaundice, hepatitis, acute hepatic failure) including fatal case reports with doses &ge;100 mg/day. Hepatotoxicity typically develops after a few weeks to several months of treatment initiation. Use in patients with prior or existing hepatic disease is contraindicated. Use caution with concurrent use of other hepatotoxic drugs. Monitor hepatic function and discontinue in patients with evidence of hepatic injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: May increase HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased; use with caution in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory effects: Shortness of breath was commonly observed in patients receiving doses of 300 mg/day; use caution in patients with existing pulmonary dysfunction (may be more susceptible to effects).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolism: May increase the risk of thromboembolism (particularly when used in combination with ethinyl estradiol); discontinue use immediately with signs/symptoms of thrombophlebitis or thromboembolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in conditions that may be aggravated by fluid retention, or cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with a history of depression (contraindicated in severe chronic depression); has been associated with an increased incidence of depression, particularly early in the course of therapy (initial 6-8 weeks).  Monitor closely in patients with tendency toward depressive episodes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes or impaired glucose tolerance, may cause alterations in glucose metabolism; may require adjustments in diabetes medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol consumption: Although the relevance to the treatment of prostate cancer is unknown, the antiandrogen effects in hypersexuality may be reduced with ethanol. Ethanol should be avoided during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Combination therapy: Retrospective meta-analysis data suggest that 5-year survival rates may be lower when used concomitantly with a GnRH agonist or orchiectomy versus patients treated with castration alone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [Canadian Boxed Warning]:",
"     </b>",
"     Should be prescribed and managed by a clinician experienced with hormonal therapy in prostate cancer.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C8 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP1A2 (weak/moderate), CYP2E1 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Progestins. Management: Progestin-containing contraceptives are not recommended; consider the use of alternative, nonhormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: Cyproterone may decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2E1 Substrates: Cyproterone may decrease the serum concentration of CYP2E1 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Cyproterone may increase the serum concentration of HMG-CoA Reductase Inhibitors.  Management: Avoid use of statins metabolized by CYP3A4 (eg, simvastatin) and consider avoiding fluvastatin as well in patients receiving high dose cyproterone (300 mg/day). Consider use of pravastatin, rosuvastatin, or pitavastatin if statin therapy is needed.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pitavastatin; Pravastatin; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F155790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May reduce the effect of cyproterone (not established in the treatment of prostatic carcinoma); avoid concurrent use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease cyproterone levels.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F155782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not indicated for use in women. In males, sperm count and volume of ejaculate will be reduced at oral doses of 50-300 mg/day. After ~2 months of treatment, infertility may be noted. Changes are reversible upon discontinuation of therapy, usually within 3-5 months although in some patients may take up to 20 months.  Production of abnormal spermatozoa has been observed although the effect on fertilization or embryo formation is unknown.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9480488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets should be taken after meals.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F155773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests should be performed at baseline and periodically thereafter, or with signs or symptoms suggestive of hepatotoxicity. CBC, adrenal function, electrolytes, fasting blood glucose and glucose tolerance (diabetic patients) should be monitored periodically. In patients with PSA progression, monitor for withdrawal response syndrome (eg, decrease in PSA levels) for 6-8 weeks following therapy discontinuation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Treatment of paraphilia/hypersexuality (Guay 2009; Reilly, 2000): ECG; hepatic function test (baseline and during treatment if suspected hepatotoxicity); CBC (baseline); serum testosterone (baseline then monthly for 4 months then every 6 months); serum luteinizing hormone and prolactin (baseline and every 6 months); follicle-stimulating hormone (baseline); glucose; bone scan (baseline then annually) if serum testosterone significantly suppressed; blood pressure; weight gain",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F155783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Androcur (AR, AT, AU, BE, BG, BR, CH, CL, CO, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, HK, HN, ID, IE, IL, IT, JP, KP, MX, MY, NL, PE, PK, PL, PT, SE, SG, TH, TW, UY, VE, ZA);",
"     </li>",
"     <li>",
"      Androstat (EC, PY);",
"     </li>",
"     <li>",
"      Armocur (IL);",
"     </li>",
"     <li>",
"      Ciproplex (PY);",
"     </li>",
"     <li>",
"      Ciproterona (CN);",
"     </li>",
"     <li>",
"      Cyprohexal (AU);",
"     </li>",
"     <li>",
"      Cypron 50 (IL, MY);",
"     </li>",
"     <li>",
"      Cyprone (AU);",
"     </li>",
"     <li>",
"      Cyproplex (BE, TW);",
"     </li>",
"     <li>",
"      Cyprostat (AU, GB);",
"     </li>",
"     <li>",
"      Cyrona (TW);",
"     </li>",
"     <li>",
"      Kaliale (FR);",
"     </li>",
"     <li>",
"      Procur (NZ, SG);",
"     </li>",
"     <li>",
"      Prostaden (UY);",
"     </li>",
"     <li>",
"      Siterone (NZ);",
"     </li>",
"     <li>",
"      Virilit (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F155766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cyproterone is a steroid with antiandrogenic, antigonadotropic, and progestin-like activity. Blocks binding of dihydrotestosterone (DHT) to prostatic cancer cells and exerts negative feedback on hypothalamic-pituitary axis by inhibiting luteinizing hormone (LH) secretion leading to decreased testosterone production.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F155780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, some metabolites have activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Oral: 38 hours (range: 33-43 hours); Depot injection: 4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Oral: 3-4 hours; Depot injection: 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (60%); urine (33%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Guay DR, &ldquo;Drug Treatment of Paraphilic and Nonparaphilic Sexual Disorders,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2009, 31(1):1-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14374/abstract-text/19243704/pubmed\" id=\"19243704\" target=\"_blank\">",
"        19243704",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lukka H, Waldron T, Klotz L, et al, \"Maximal Androgen Blockade for the Treatment of Metastatic Prostate Cancer-- A Systematic Review,\"",
"      <i>",
"       Curr Oncol",
"      </i>",
"      , 2006, 13(3):81-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14374/abstract-text/17576447/pubmed\" id=\"17576447\" target=\"_blank\">",
"        17576447",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reilly DR, Delva NJ, and Hudson RW, &ldquo;Protocols for the Use of Cyproterone, Medroxyprogesterone, and Leuprolide in the Treatment of Paraphilia,&rdquo;",
"      <i>",
"       Can J Psychiatry",
"      </i>",
"      , 2000, 45(6):559-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14374/abstract-text/10986575/pubmed\" id=\"10986575\" target=\"_blank\">",
"        10986575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schroder FH, \"Cyproterone Acetate--Mechanism of Action and Clinical Effectiveness in Prostate Cancer Treatment,\"",
"      <i>",
"       Cancer",
"      </i>",
"      , 1993, 72(12 Suppl):3810-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14374/abstract-text/8252496/pubmed\" id=\"8252496\" target=\"_blank\">",
"        8252496",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thibaut F, De La Barra F, Gordon H, et al, &ldquo;The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Paraphilias,&rdquo;",
"      <i>",
"       World J Biol Psychiatry",
"      </i>",
"      , 2010, 11(4):604-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14374/abstract-text/20459370/pubmed\" id=\"20459370\" target=\"_blank\">",
"        20459370",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9295 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F93BED5DA7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_2_14374=[""].join("\n");
var outline_f14_2_14374=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155793\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155804\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155794\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062977\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155795\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155796\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241394\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11218428\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155778\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155777\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15070678\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155802\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155781\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155767\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299112\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219608\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155790\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155782\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9480488\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155773\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155783\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155766\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155780\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9295\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9295|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/15/6389?source=related_link\">",
"      Cyproterone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_2_14375="Exenatide: Drug information";
var content_f14_2_14375=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Exenatide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/59/26550?source=see_link\">",
"    see \"Exenatide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16339632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Investigating Unpublished Reports of Pancreatic Toxicity With Incretin Mimetic Drugs",
"     </span>",
"     <span class=\"collapsible-date\">",
"      March 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Food and Drug Administration (FDA) is evaluating unpublished new findings that suggest an increased risk of pancreatitis and pancreatic duct metaplasia in patients with type 2 diabetes treated with incretin mimetics. These findings are based on pancreatic tissue samples taken from patients who died from unspecified causes. The FDA has requested these samples, as well as information on the methodology used to collect them, and will communicate its final conclusions and recommendations. Healthcare providers should continue to prescribe incretin mimetics according to the drug label recommendations and patients receiving incretin mimetics are advised to continue therapy as directed and to discuss any concerns with their healthcare provider.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at the following website:",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm343187.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm343187.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13796080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F595798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bydureon&trade;;",
"     </li>",
"     <li>",
"      Byetta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14204425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Byetta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F595883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F595906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Adjunctive therapy of type 2 diabetes:",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release: Initial: 5 mcg twice daily within 60 minutes prior to a meal; after 1 month, may be increased to 10 mcg twice daily (based on response)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release: 2 mg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     May administer a missed dose as soon as noticed if the next regularly scheduled dose is due in &ge;3 days; resume normal schedule thereafter. To establish a new day of the week administration schedule, wait &ge;3 days after last dose given, then administer next dose on new desired day of the week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <i>",
"      Conversion from immediate release to extended release:",
"     </i>",
"     Initiate weekly administration of exenatide extended release the day after discontinuing exenatide immediate release.",
"     <b>",
"      Note:",
"     </b>",
"     May experience increased blood glucose levels for ~2 weeks after conversion. Pretreatment with immediate release exenatide is not required when initiating extended release exenatide.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F595907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F595908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: No dosage adjustment provided in manufacturer's labeling; use caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     U.S. labeling: Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Canadian labeling: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13796181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); however, hepatic dysfunction is not expected to affect exenatide pharmacokinetics.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F595910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, microspheres for suspension, extended release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bydureon&trade;: 2 mg [contains polylactide-co-glycolide, sucrose 0.8 mg/vial; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Byetta&reg;: 250 mcg/mL (2.4 mL) [10 mcg/0.04 mL; 60 doses]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Byetta&reg;: 250 mcg/mL (1.2 mL) [5 mcg/0.02 mL; 60 doses]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F595803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10110709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Bydureon&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM289869.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM289869.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Byetta&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM191084.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM191084.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F595800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release: Use only if clear, colorless, and free of particulate matter. Administer via injection in the upper arm, thigh, or abdomen. Administer within 60 minutes prior to  morning and evening meal (or prior to the 2 main meals of the day, approximately &ge;6 hours apart).  Set up each new pen before the first use by priming it. See pen user manual for further details. Dial the dose into the dose window before each administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release: Administer via injection in the upper arm, thigh, or abdomen; rotate injection sites weekly.  Administer immediately after reconstitution.  May administer without regard to meals or time of day.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F595819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type 2 diabetes mellitus (noninsulin dependent, NIDDM) to improve glycemic control",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F595845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia (monotherapy 2% to 5%; combination therapy with sulfonylurea 14% to 36%, with metformin &le;4%, with thiazolidinedione 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Nausea (monotherapy 8% to 11%; combination therapy 13% to 44%; dose-dependent), vomiting (monotherapy 4%; combination therapy 11% to 13%), diarrhea (monotherapy &lt;2% to 11%; combination therapy 6% to 20%), constipation (monotherapy 9%; combination therapy 6% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Local: Injection site nodule (Bydureon&trade; 6% to 77%), injection site reactions (2% to 18%; includes erythema, hematoma, pruritus)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Anti-exenatide antibodies (low titers 38% to 49%, high titers 6% to 12%)",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Central nervous system: Nervousness (9%), dizziness (monotherapy &lt;2%; combination therapy 9%), headache (5% to 9%), fatigue (3% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Hyperhidrosis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Viral gastroenteritis (6% to 9%), dyspepsia (monotherapy 3% to 7%; combination therapy 5% to 7%), GERD (3% to 7%), appetite decreased (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Postmarketing and/or case reports (Limited to important or life-threatening): Alopecia, anaphylactic reaction, angioedema, hypersensitivity pneumonitis, influenza, pancreatitis (including hemorrhagic and necrotizing), rash, renal failure, renal impairment, upper respiratory tract infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F595820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to exenatide or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Bydureon&trade;: Additional contraindications: History of or family history of medullary thyroid carcinoma (MTC); patients with multiple endocrine neoplasia syndrome type 2 (MEN2)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Byetta&trade;: Canadian labeling: Additional contraindications (not in U.S. labeling): End-stage renal disease or severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) including dialysis patients; diabetic ketoacidosis, diabetic coma/precoma or type 1 diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F595841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anti-exenatide antibodies: Use may be associated with the development of anti-exenatide antibodies. Low titers are not associated with a loss of efficacy; however, high titers (observed in 6% to 12% of patients in clinical studies) may result in an attenuation of response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; GI symptoms: Most common reactions are gastrointestinal related; these symptoms may be dose-related and may decrease in frequency/severity with gradual titration and continued use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: Cases of acute pancreatitis (including hemorrhagic and necrotizing with some fatalities) have been reported; monitor for unexplained severe abdominal pain, and if pancreatitis is suspected, discontinue use. Do not resume unless an alternative etiology of pancreatitis is confirmed. Consider alternative antidiabetic therapy in patients with a history of pancreatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid tumors: Bydureon&trade;:",
"     <b>",
"      [U.S. Boxed Warning] Dose- and duration-dependent thyroid C-cell tumors have developed in animal studies with exenatide extended release therapy; relevance in humans unknown.",
"     </b>",
"     Patients should be counseled on the risk and symptoms (eg, neck mass, dysphagia, dyspnea, persistent hoarseness) of thyroid tumors. Consultation with an endocrinologist is recommended in patients who develop elevated calcitonin concentrations or have thyroid nodules detected during imaging studies or physical exam; routine monitoring of serum calcitonin or using thyroid ultrasound for early detection of medullary thyroid carcinoma (MTC) is of unknown value (due to risk of unnecessary procedures and low specificity of serum calcitonin testing for MTC). Use is contraindicated in patients with a personal or a family history of medullary thyroid cancer and in patients with multiple endocrine neoplasia syndrome type 2 (MEN2). All cases of MTC should be reported to the applicable state cancer registry. Cases of thyroid C-cell hyperplasia in humans have been reported with the GLP-1 agonist, liraglutide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight loss: Use may be associated with weight loss (due to reduced intake) independent of the change in hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes, type 1: Mechanism requires the presence of insulin, therefore use in type 1 diabetes (insulin dependent, IDDM) or diabetic ketoacidosis is not recommended (use is contraindicated in the Canadian labeling); it is not a substitute for insulin in insulin-requiring patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Not recommended to be used in patients with gastroparesis or severe gastrointestinal disease due to frequent gastrointestinal adverse effects associated with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use not recommended in severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) or end-stage renal disease (ESRD) (use in these patients and in dialysis patients is contraindicated in the Canadian labeling). Patients with ESRD receiving dialysis may be more susceptible to GI effects (eg, nausea, vomiting) which may result in hypovolemia and further reductions in renal function. Use with caution in patients with renal transplantation or in patients with moderate renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute), particularly when initiating or escalating doses with immediate release exenatide. Cases of acute renal failure and chronic renal failure exacerbation, including severe cases requiring hemodialysis, have been reported, predominately in patients with nausea/vomiting/diarrhea or dehydration; renal dysfunction was usually reversible with appropriate corrective measures, including discontinuation of exenatide. Risk may be increased in patients receiving concomitant medications affecting renal function and/or hydration status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duplicate therapy: Avoid concurrent use of extended release (weekly) and immediate release (daily) exenatide formulations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Insulin: Concurrent use with insulin therapy has not been evaluated and is not recommended. (Exception: Safety and efficacy of concurrent insulin glargine and immediate release exenatide has been demonstrated in a clinical trial.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Insulin secretagogues: Concomitant use of an insulin secretagogue (eg, sulfonylurea, meglitinide) may increase the risk of hypoglycemia; dosage reduction of sulfonylureas may be required. Clinicians should note that the risk of hypoglycemia is not increased when exenatide is added to metformin monotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral medications: Due to its effects on gastric emptying, exenatide may reduce the rate and extent of absorption of orally-administered drugs; use with caution in patients receiving medications with a narrow therapeutic window or require rapid absorption from the GI tract. Administer medications 1 hour prior to the use of immediate release (daily) exenatide when optimal drug absorption and peak levels are important to the overall therapeutic effect (eg, antibiotics, oral contraceptives); effects of extended release (weekly) exenatide on drug absorption have not been evaluated; however, use caution as the potential for drug-drug interaction with extended release exenatide is expected to be similar to that of immediate release exenatide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Bydureon&trade;: Not recommended for first-line therapy in patients inadequately controlled on diet and exercise alone.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F595848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Exenatide may decrease the serum concentration of Contraceptives (Estrogens).  Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral Contraceptive (Progestins): Exenatide may decrease the serum concentration of Oral Contraceptive (Progestins).  Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: GLP-1 Agonists may enhance the hypoglycemic effect of Sulfonylureas.  Management: Consider sulfonylurea dose reductions when used in combination with GLP-1 agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Exenatide may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F595850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Ethanol may cause hypoglycemia. Management: Consume ethanol with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Administer Byetta&reg; within 60 minutes of meals, not after meals. May administer Bydureon&trade; without regard to meals or time of day.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F595804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F595805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to adverse events observed in some animal studies, exenatide is classified as pregnancy category C. Based on",
"     <i>",
"      in vitro",
"     </i>",
"     data, exenatide has a low potential to cross the placenta. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is above the normal range. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the mother and the fetus. Until additional safety and efficacy data are obtained, the use of exenatide is generally not recommended in the routine management of diabetes mellitus during pregnancy. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy. A registry has been established for women exposed to exenatide during pregnancy (1-800-633-9081).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F595806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6207220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if exenatide is present in breast milk. The manufacturer recommends that caution be exercised when administering exenatide to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Byetta 10 MCG Pen Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mcg/0.04 mL (2.4 mL): $378.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Byetta 5 MCG Pen Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mcg/0.02 mL (1.2 mL): $378.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Bydureon Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (1): $104.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F595904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum glucose, hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"     , and renal function",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F9631065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bydureon (GB);",
"     </li>",
"     <li>",
"      Byetta (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CZ, DE, DK, EE, FI, FR, GB, GR, HK, HN, IE, IL, IT, KP, MT, MY, NL, NO, NZ, PH, PL, PT, RU, SE, SG, SK, TH, TR, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F595853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exenatide is an analog of the hormone incretin (glucagon-like peptide 1 or GLP-1) which increases glucose-dependent insulin secretion, decreases inappropriate glucagon secretion, increases B-cell growth/replication, slows gastric emptying, and decreases food intake. Exenatide administration results in decreases in hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"     by approximately 0.5% to 1% (immediate release) or 1.5% to 1.9% (extended release).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F595855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 28.3 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Minimal systemic metabolism; proteolytic degradation may occur following glomerular filtration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Immediate release (daily) formulation: 2.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extended release (weekly) formulation: ~2 weeks",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Time to peak, plasma: SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Immediate release (daily) formulation: 2.1 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extended release (weekly) formulation: Triphasic: Phase 1: 2-5 hours; Phase 2: ~2 weeks; Phase 3: ~7 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (majority of dose)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14375/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blevins T, Pullman J, Malloy J, et al, \"DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared With Exenatide Twice Daily in Patients With Type 2 Diabetes,\"",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2011, 96(5):1301-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14375/abstract-text/ 21307137/pubmed\" id=\" 21307137\" target=\"_blank\">",
"        21307137",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buse JB, Drucker DJ, Taylor KL, et al, \"DURATION-1 Study Group. DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks,\"",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2010, 33(6):1255-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14375/abstract-text/20215461/pubmed\" id=\"20215461\" target=\"_blank\">",
"        20215461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buse JB, Henry RR, Han J, et al, \"Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type-2 Diabetes,\"",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2004, 27(11):2628-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14375/abstract-text/15504997/pubmed\" id=\"15504997\" target=\"_blank\">",
"        15504997",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Defronzo RA, Ratner RE, Han J, et al, \"Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type-2 Diabetes,\"",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2005, 28(5):1092-1100.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14375/abstract-text/15855572/pubmed\" id=\"15855572\" target=\"_blank\">",
"        15855572",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeYoung MB, MacConell L, Sarin V, et al, \"Encapsulation of Exenatide in Poly-(D,L-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes, \"",
"      <i>",
"       Diabetes Technol Ther",
"      </i>",
"      , 2011, 13(11):1145-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14375/abstract-text/21751887/pubmed\" id=\"21751887\" target=\"_blank\">",
"        21751887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diamant M, Van Gaal L, Stranks S, et al, \"Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks,\"",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(4):683-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14375/abstract-text/22357185/pubmed\" id=\"22357185\" target=\"_blank\">",
"        22357185",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Drucker DJ, Buse JB, Taylor K, et al, \"DURATION-1 Study Group. Exenatide Once Weekly Versus Twice Daily For The Treatment Of Type 2 Diabetes: A Randomised, Open-Label, Non-Inferiority Study,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2008, 372(9645):1240-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14375/abstract-text/18782641/pubmed\" id=\"18782641\" target=\"_blank\">",
"        18782641",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fineman MS, Shen LZ, Taylor K, et al, \"Effectiveness of Progressive Dose-Escalation of Exenatide (Exendin-4) in Reducing Dose-Limiting Side Effects in Subjects With Type 2 Diabetes,\"",
"      <i>",
"       Diabetes Metab Res Rev",
"      </i>",
"      , 2004, 20(5):411-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14375/abstract-text/15343588/pubmed\" id=\"15343588\" target=\"_blank\">",
"        15343588",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Handelsman Y, Mechanick JI, Blonde L, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2011, 17(Suppl 2):1-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14375/abstract-text/21474420/pubmed\" id=\"21474420\" target=\"_blank\">",
"        21474420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Joy SV, Rodgers PT, and Scates AC, \"Incretin Mimetics as Emerging Treatments for Type 2 Diabetes,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(1):110-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14375/abstract-text/15562141/pubmed\" id=\"15562141\" target=\"_blank\">",
"        15562141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kendall DM, Riddle MC, Rosenstock J, et al, \"Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea,\"",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2005, 28(5):1083-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14375/abstract-text/15855571/pubmed\" id=\"15855571\" target=\"_blank\">",
"        15855571",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkman M, Briscoe VJ, Clark N, et al, \"Diabetes in Older Adults: A Consensus Report,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012; doi: 10.1111/jgs.12035.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14375/abstract-text/23106132/pubmed\" id=\"23106132\" target=\"_blank\">",
"        23106132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moretto TJ, Milton DR, Ridge TD, et al, &ldquo;Efficacy and Tolerability of Exenatide Monotherapy Over 24 Weeks in Antidiabetic Drug-Na&iuml;ve Patients With Type 2 Diabetes: A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group Study,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2008, 30(8):1448-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14375/abstract-text/18803987/pubmed\" id=\"18803987\" target=\"_blank\">",
"        18803987",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Movassat J, Beattie GM, Lopez AD, et al, \"Exendin 4 Up-Regulates Expression of PDX 1 and Hastens Differentiation and Maturation of Human Fetal Pancreatic Cells,\"",
"      <i>",
"       J Clin Endocrinol Metab,",
"      </i>",
"      2002, 87(10):4775-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14375/abstract-text/12364473/pubmed\" id=\"12364473\" target=\"_blank\">",
"        12364473",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nathan DM, Buse JB, Davidson MB, et al, &ldquo;Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2009, 32(1):193-203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14375/abstract-text/18945920/pubmed\" id=\"18945920\" target=\"_blank\">",
"        18945920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al, &ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14375/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodbard HW, Jellinger PS, Davidson JA, et al, &ldquo;Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(6):540-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/2/14375/abstract-text/19858063/pubmed\" id=\"19858063\" target=\"_blank\">",
"        19858063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9005 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-202.43.93.2-49404BB9CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_2_14375=[""].join("\n");
var outline_f14_2_14375=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16339632\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13796080\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595798\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14204425\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595883\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595906\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595907\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595908\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13796181\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595910\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595803\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10110709\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595800\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595819\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595845\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595820\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595841\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299306\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595848\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595850\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595804\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595805\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595806\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6207220\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422177\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595904\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9631065\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038860\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595853\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595855\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9005\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9005|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/59/26550?source=related_link\">",
"      Exenatide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_2_14376="Radiation dose and risk of malignancy from cardiovascular imaging";
var content_f14_2_14376=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Radiation dose and risk of malignancy from cardiovascular imaging",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/2/14376/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/2/14376/contributors\">",
"     Thomas C Gerber, MD, PhD, FACC, FAHA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/2/14376/contributors\">",
"     Andrew J Einstein, MD, PhD, FACC, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/2/14376/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/2/14376/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/2/14376/contributors\">",
"     Patricia A Pellikka, MD, FACC, FAHA, FASE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/2/14376/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/2/14376/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/2/14376/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of diagnostic cardiovascular imaging has increased rapidly over the past decade owing to developments in technology, increased availability, and the perception that imaging can meaningfully affect medical decision making. Studies documenting increasing medical radiation exposure, particularly from cardiovascular imaging, have raised concerns about potential health risks associated with this exposure and have been highly publicized in the professional and lay literature [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several of the major imaging modalities for cardiovascular diagnosis and treatment use ionizing radiation. Radionuclide myocardial perfusion imaging (rMPI) in the form of single photon emission computed tomography (SPECT) and positron emission tomography (PET) use radionuclides that produce both photon and particulate radiation. Sources of x-ray radiation include cardiovascular computed tomography (CVCT), which is used for imaging coronary artery plaque and calcification, and x-ray fluoroscopy, which is used to guide established and emerging diagnostic and therapeutic electrophysiologic, coronary, and other cardiovascular procedures.",
"   </p>",
"   <p>",
"    The potential risks of imaging tests that use ionizing radiation must be weighed against the potential benefits of these tests. This assessment is difficult since the health risks related to radiation exposure at the levels common in cardiovascular imaging are controversial. In addition, limited evidence is available on the impact of these tests on clinical outcomes.",
"   </p>",
"   <p>",
"    This topic will discuss radiation exposure and potential risks from cardiovascular imaging. Various cardiovascular imaging tests and radiation-related risk of medical imaging studies generally are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RADIATION DOSIMETRY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some radiation dosimetry parameters can be measured whereas others are estimates that are modeled using complex assumptions and simulations. Parameters of radiation dosimetry readily derived from physical measurements of radiation exposure (in",
"    <span class=\"nowrap\">",
"     Coulomb/kg,",
"    </span>",
"    <span class=\"nowrap\">",
"     C/kg)",
"    </span>",
"    include the entrance skin dose in radiography and fluoroscopy (in units of milliGray, mGy), and the volume computed tomographic dose index (CTDIvol, in mGy) and the dose-length product (DLP, in mGy x cm) in computed tomography (CT) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. These parameters are extremely useful to establish so-called \"diagnostic reference levels\" for quality control and benchmarking among institutions that perform cardiac imaging with ionizing radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/5\">",
"     5",
"    </a>",
"    ]. For example, consistently exceeding the 75th to 80th percentile as established in radiation dose surveys should suggest to an individual institution the need for reevaluation and change of practices. Establishing reference values has been shown to reduce the median dose and interinstitutional dose variability of radiological procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Parameters of radiation dosimetry are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4106?source=see_link\">",
"     \"Biology and clinical features of radiation injury in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effective dose (E, expressed in units of milliSievert, mSv) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/8\">",
"     8",
"    </a>",
"    ], the radiation dose parameter most frequently reported in medical journals, is a broad estimate of the risk of biologic detriment from a partial body exposure to ionizing radiation that allows comparisons between different imaging protocols, between different types of radiological examinations or between man-made and natural sources of radiation. Conversely, because E is estimated based on generic mathematical models of the human body and does not take into account variations of human anatomy, E cannot be used to compare radiation doses for the same type of procedure between different patients. There is no measurable physical gold standard for E. Given the complex modeling and many assumptions involved with the estimation of E, E should generally be reported as ranges, not at specific values with decimal precision [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Confusion between E and reported organ doses should be avoided. Estimation of organ doses is one of several steps in the estimation of E and there are various types of organ doses. To avoid possible ambiguity, the dose to an organ should best be described as the organ's",
"    <strong>",
"     absorbed dose",
"    </strong>",
"    , expressed in units of mGy. However, sometimes the organ",
"    <strong>",
"     equivalent dose",
"    </strong>",
"    expressed in mSv is reported and can be mistaken for E because they share the same unit of measurement although their values differ. For example, in cardiac CT imaging, the numerical value of the equivalent dose of the breast is typically several times higher than that of E.",
"   </p>",
"   <p>",
"    Individualization of dose and risk estimates is complex and inherently imperfect. Longitudinal tracking of individual cumulative lifetime dose of nontherapeutic medical radiation in patients is currently not standard because of its logistical challenges and disagreement as to its usefulness and societal value [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/10\">",
"     10",
"    </a>",
"    ]. Efforts are underway to develop pertinent information systems [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Radiation doses associated with medical imaging",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the National Council on Radiation Protection and Measurement (NCRP) report No. 160 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], the collective medical radiation dose to the US population (excluding dental and radiotherapy) increased by 730 percent from 123,7000 person-Sv in the early 1980s, when the last similar surveys were performed, to 899,000 person-Sv in 2006. These numbers appear dramatic, but collective dose has been criticized as a measure since a large dose delivered to a small number of people is not the same as a small dose delivered to many people. The collective dose does not account for the fact that by far the largest proportion of the population-averaged radiation dose is delivered to the ill and elderly. The annual total radiation exposure to individuals who are NOT exposed to",
"    <strong>",
"     medical",
"    </strong>",
"    ionizing radiation has generally changed only modestly since 1982.",
"   </p>",
"   <p>",
"    The highest proportion of the collective dose of nontherapeutic medical radiation (49 percent) in 2006 was related to computed tomography (CT), the use of which increased by 10 to 11 percent per year from 18.3 million studies in 1993 to 62 million in 2006. In 2006, CVCT represented 4.7 percent of all CT studies and 12.1 percent of the collective dose received from CT, according to this NCRP report.",
"   </p>",
"   <p>",
"    Nuclear medicine studies represented 26 percent of the collective dose in 2006. The use of nuclear medicine studies increased over fourfold from 7.6 million in 1982 to an estimated 18.1 million in 2006. The highest increase in utilization was related to cardiac imaging. In 2005, cardiac imaging studies represented 57 percent of patient visits related to nuclear medicine (increased from 1 percent in 1973) and 85 percent of the collective dose received from nuclear medicine studies.",
"   </p>",
"   <p>",
"    In a study using administrative claims data for over 950,000 nonelderly insured adults, 9.5 percent underwent at least one cardiac imaging procedure during 2005 to 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/14\">",
"     14",
"    </a>",
"    ]. Among those receiving &ge;1 cardiac imaging procedures, the estimated mean cumulative effective dose over three years from cardiac imaging was 23.1 mSv (range 1.5 to 543.7 mSv). Most (74 percent) of the cumulative effective dose was from radionuclide myocardial perfusion imaging (rMPI).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Radiation dose and determinants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accompanying table lists representative values and ranges of effective dose estimates from the literature for various radiologic imaging studies (",
"    <a class=\"graphic graphic_table graphicRef50090 \" href=\"UTD.htm?4/60/5069\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef70759 \" href=\"UTD.htm?15/41/16030\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/10\">",
"     10",
"    </a>",
"    ]. The dose-saving strategies in CT that are reflected in this table are discussed in the next section. For comparison, the average annual background radiation in the United States is approximately 3 mSv (range, 1 to 10 mSv) and the radiation dose received during a six-hour commercial airline flight is approximately 0.03 mSv.",
"   </p>",
"   <p>",
"    In fluoroscopy, the principal determinants of radiation exposure are patient habitus, operator technique and procedural complexity (which affect exposure time), and the x-ray system and its selected settings. An evaluation of fluoroscopic exposure rates in 41 cardiac catheterization laboratory systems using a standardized methodology revealed a four- to sixfold variation among systems [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/15\">",
"     15",
"    </a>",
"    ]. Exposure rates under simulated medium habitus conditions varied over sixfold from less than 0.3 to 1.7",
"    <span class=\"nowrap\">",
"     mC/kg/min,",
"    </span>",
"    with a median of 0.8",
"    <span class=\"nowrap\">",
"     mC/kg/min.",
"    </span>",
"    Only 25 percent of systems had satisfactory image quality at a low exposure rate. In a review of almost 1000 coronary procedures performed at the Mayo Clinic during 1997, the median exposure was 35",
"    <span class=\"nowrap\">",
"     mC/kg",
"    </span>",
"    for diagnostic procedures and 96",
"    <span class=\"nowrap\">",
"     mC/kg",
"    </span>",
"    for interventional procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mean duration of fluoroscopy in electrophysiologic interventional procedures was 41 minutes in one report, with a range of 15 to 67 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/17\">",
"     17",
"    </a>",
"    ]. A typical procedure resulted in a total effective dose of 8.3 mSv per hour of fluoroscopy. The mean fluoroscopy time was typically longer, and thus radiation exposure was greater, for paroxysmal atrial fibrillation than for common atrial flutter or accessory pathway ablation: 57 versus 20 to 22 minutes in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/18\">",
"     18",
"    </a>",
"    ] and 130 versus 30 and 17 minutes in another [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/19\">",
"     19",
"    </a>",
"    ]. As mentioned above, patient-specific factors can also affect radiation dose. In a series of 85 patients undergoing pulmonary vein isolation procedures for the treatment of atrial fibrillation, obese patients received more than twice the effective radiation dose of normal-weight patients (mean 39 versus 15 mSv) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Effective radiation doses from CT imaging vary with equipment, patient size, and body parts imaged. In addition, wide variation (eg, mean 13-fold) in effective radiation dose within CT study types has been observed within and across institutions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/21\">",
"     21",
"    </a>",
"    ]. Facilities performing full-body CT (FBCT) imaging for \"screening\" purposes often adjust radiation doses to levels 20 to 50 percent below typical diagnostic studies to market so called \"low-dose CT scans.\" However, too low a dose relative to patient size may result in images that have limited diagnostic value. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link&amp;anchor=H6024332#H6024332\">",
"     \"Radiation-related risks of imaging studies\", section on 'CT examinations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In CVCT, examinations performed to quantify coronary artery calcification generally impart a lower dose than examinations performed for coronary CT angiography (CCTA) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/10\">",
"     10",
"    </a>",
"    ]. Among the multidetector row scanners (MDCT or MSCT) used for CVCT, scanners with a higher number of detector rows or \"slices\" (typically 4 in 1999, 16 in 2003, 64 in 2005, and most recently as many as 320) typically impart a higher radiation dose using the standard helical technique, although many newer scanners incorporate scanning and reconstruction algorithms that enable significant radiation dose reductions. As a result of differences in scanner setting and imaging protocols, the effective dose received from CCTA can differ substantially (eg, sixfold variation between institutions in a multinational survey [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/22\">",
"     22",
"    </a>",
"    ]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6237370\">",
"    <span class=\"h3\">",
"     Multiple testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients frequently undergo multiple medical tests involving radiation exposure leading to high cumulative doses of radiation. This was illustrated by a retrospective cohort study of 1097 consecutive patients undergoing radionuclide myocardial perfusion imaging (rMPI) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/23\">",
"     23",
"    </a>",
"    ]. During an approximately 20 year period, the patients underwent a median of 15 (interquartile range, 6-32; mean 23.9) procedures involving radiation exposure. Of these, a median of four (mean, 6.5) were high dose procedures (&ge;3 mSv) including 1 (mean, 1.8) rMPI study per patient. The cumulative estimated effective dose from all medical sources exceeded 100 mSv in 31.4 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Options for reducing radiation dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing diagnostic testing and interventional catheter-based percutaneous procedures may receive substantial radiation exposure. The first step in reducing radiation exposure is use of testing and management strategies that are medically appropriate with careful assessment of individualized potential risks and benefits. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Balancing risks and benefits'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The operator of a procedure entailing radiation exposure has an obligation to expose the patient and the staff to the minimal dose of radiation needed to complete the procedure successfully. Particularly in complex electrophysiologic procedures such as ablation for atrial fibrillation, newer imaging and mapping techniques have reduced fluoroscopy times. Pulse fluoroscopy and optimization of fluoroscopy exposure parameters also reduce the risk of radiation injury.",
"   </p>",
"   <p>",
"    In radionuclide imaging, choice of the radiopharmaceutical, individualized adjustment of the injected activity, use of sensitive equipment and improved reconstruction algorithms, and use of one-day or stress-only protocols are among the options for reducing radiation dose.",
"   </p>",
"   <p>",
"    The radiation dose of CVCT can be reduced with certain scan techniques, some of which may affect image quality. The most basic approach, which requires some experience on the part of the performing health care provider, is individualized adjustment of scan parameters such as tube voltage and scan length that take into account the variability of anatomy between different patients. CVCT-specific software-based modifications of common CT scanning protocols are available. For example, ECG-controlled tube current modulation (ECTCM) markedly reduces the output of the x-ray tube during certain portions of the cardiac cycle when so-called retrospective gating is used. The benefit of ECG-dependent dose modulation is reduced at higher heart rates with standard single-source CCTA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/24\">",
"     24",
"    </a>",
"    ], but not with dual source CCTA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/25\">",
"     25",
"    </a>",
"    ]. Prospectively triggered sequential scanning is a newer scan mode on multidetector scanners that produces radiation only during predetermined portions of the cardiac cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/26\">",
"     26",
"    </a>",
"    ]. Other new dose-reduction methods include iterative reconstruction, whole-heart volume scanning, and high-pitch helical scanning.",
"   </p>",
"   <p>",
"    In a statewide registry of a collaborative radiation dose-reduction program that included education on a best-practice CCTA scan model using some or all of these techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/27\">",
"     27",
"    </a>",
"    ], the mean E of CCTA was reduced by 53 percent from 21 mSv to 10 mSv over the course of a year. In an international, multicenter survey of radiation dose in CCTA performed in 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/22\">",
"     22",
"    </a>",
"    ], ECTCM lowered E by 25 percent, reduction of tube voltage (from 120 to 100 kVp) reduced E by 46 percent, and sequential scanning reduced E by 78 percent. ECTCM was used in 73 percent of patients, but the most effective dose reduction strategies were rarely used (sequential scanning, in 6 percent or patients and reduction of tube voltage, in 5 percent). This may have been in part because of concerns that dose-sparing scanning protocols may interfere with image quality and diagnostic accuracy of CCTA. However, in several recent direct comparisons between conventional retrospectively gated and newer prospectively triggered scanning [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/28,29\">",
"     28,29",
"    </a>",
"    ], subjective image quality and diagnostic accuracy were similar whereas radiation dose was substantially lower in the latter group (21 and 21 mSv versus 4 and 6 mSv). These data will hopefully result in wider acceptance and use of dose-saving imaging strategies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HEALTH RISKS OF RADIATION EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to ionizing radiation from medical imaging may have deterministic as well as stochastic effects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A deterministic effect is one in which severity is determined by the dose. A dose threshold (ie, a dose below which an effect is not seen) is characteristic of a deterministic effect. A skin burn is an example of a deterministic effect of ionizing radiation. Radiation exposure during prolonged fluoroscopic procedures can result in skin burns, usually with fluoroscopy times longer than 60 minutes. Those burns are often under-reported since they may not develop for weeks after the procedure. In a study on fluoroscopy used in electrophysiologic ablation procedures, one report included 859 patients undergoing ablation of the AV node or accessory pathway in which the mean duration of fluoroscopy was 53 minutes [",
"      <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/30\">",
"       30",
"      </a>",
"      ]. The radiation dose needed to cause radiation skin injury was exceeded during 22 percent of procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. Patients with repeated doses of radiation to the same skin entry portal may be at increased risk.",
"     </li>",
"     <li>",
"      A stochastic effect represents an outcome for which the probability of occurrence (rather than severity) is determined by the dose. An example is radiation-induced carcinogenesis, which occurs after a typically prolonged but variable delay (latency) after exposure. These effects may not have an apparent threshold dose. The stochastic consequences of exposure to ionizing radiation at the doses used in medical imaging for public and individual patient health are somewhat controversial. The radiation sensitivity of biological cells is related to the rate of proliferation, number of future divisions, and degree of differentiation. It is undisputed that ionizing radiation can cause chromosomal changes and that high doses of radiation are associated with an increase in malignancies. However, not all chromosomal changes will translate into phenotypic illness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The doses of ionizing radiation received in medical imaging are typically considerably lower than those received in nuclear explosions or accidents. Although there is controversy, the majority opinion of experts is that the health consequences resulting from whole body irradiation, as occurred in Hiroshima and Nagasaki, can be extrapolated to the \"low\" (&lt;100 mSv) dose partial body exposures that occur in medical imaging. There are epidemiological studies of atomic bomb survivors, nuclear industry workers in 15 countries, and in utero x-ray exposure that have been interpreted as being consistent with an increase in cancer risk at radiation doses comparable to those received by some patients undergoing cardiovascular imaging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/33\">",
"     33",
"    </a>",
"    ]. The strongest evidence to date relating low-dose radiation from medical imaging to increased risk of cancer derives from a cohort study of nearly 180,000 children who underwent CT scans in the United Kingdom between 1985 and 2002, in which statistically significant increases in brain cancer and leukemia were noted with doses as low as 30 mSv [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The symptoms, diagnosis, and management of acute radiation sickness and the types (deterministic versus stochastic) and nature of long-term effects that can occur in victims of nuclear explosions or accidents are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17689?source=see_link\">",
"     \"Clinical features of radiation exposure in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4106?source=see_link\">",
"     \"Biology and clinical features of radiation injury in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Potential carcinogenesis from imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defining the carcinogenic potential of ionizing radiation at the doses used in medical imaging is made difficult by the intrinsic, substantial background risk of cancer of the general population and the ubiquity of natural background radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/10\">",
"     10",
"    </a>",
"    ]. Given the many confounding issues, together with the difficulties related to determining patient-specific radiation doses accurately that are discussed above and the latency period of 10 to 40 years for most radiation-induced solid malignancies, studies designed to examine possible carcinogenic effects of ionizing radiation at the levels used in cardiovascular imaging require very large sample sizes and many years of follow-up. Such medically exposed cohorts are only beginning to be studied, and the results of numerous epidemiological investigations are expected over the next five years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the many uncertainties related to dose-response relationship of radiation exposure, radiation protection is typically discussed on the basis of the so-called \"linear no-threshold&rdquo; model. [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/36\">",
"     36",
"    </a>",
"    ]. This model holds that any level of ionizing radiation dose, no matter how low, can cause cancer and that the risk of cancer increases linearly with radiation dose. This model of dose-response is unproven but has been chosen by several influential bodies of experts concerned with radiation protection as the best simple model fitting the available data on the relationships between radiation dose and the lifetime attributable risk of cancer, with the understanding that there still remain considerable uncertainties.",
"   </p>",
"   <p>",
"    By contrast, a \"linear quadratic&rdquo; model is more complex, incorporating terms that are proportional both to dose and the square of dose. The concept of \"radiation hormesis\" [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/37\">",
"     37",
"    </a>",
"    ] dismisses any risk of cancer at low radiation dose, and instead assumes a protective effect, presumably on the basis of up-regulation of molecular cell repair mechanisms.",
"   </p>",
"   <p>",
"    It is important to realize that all published estimates of potential cancer risk related to CV imaging are based on the linear no-threshold model. Within this conceptual framework, the age- and gender-averaged lifetime risk of dying from radiation-related cancer has been estimated to be 5 to 7.9 in 100 individuals of the general population who are exposed to 1 Sv of E [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/36,38\">",
"     36,38",
"    </a>",
"    ]. The following examples illustrate published risk estimates:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis from the United Kingdom estimated that fluoroscopic radiation exposure during catheter-based coronary angiography may cause up to 280 cases of cancer per million examinations performed [",
"      <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/39\">",
"       39",
"      </a>",
"      ]. Other studies estimated that the radiation dose received from 53 to 60 minutes of fluoroscopy during electrophysiologic ablation procedures would result in 0.7 to 1.4 excess fatal malignancies per 1000 women and 1.0 to 2.6 per 1000 men [",
"      <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/19,30\">",
"       19,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The potential lifetime-attributable risk (LAR) of cancer for CCTA varies markedly with age and sex. The LAR of cancer is much greater for women (due to risk of breast cancer in addition to lung cancer), younger patients, and for combined cardiac and aortic scanning. Older age is associated with lower risk since the radiosensitivity of many organs such as breast appears to decline with age and there is typically a long latency period from radiation exposure to development of malignancy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/24,40\">",
"       24,40",
"      </a>",
"      ]. In one study, for example, a single helical 64-slice CCTA without ECTCM was associated with a lifetime cancer risk estimate of 1 in 143 (0.7 percent) in a 20-year-old woman and 1 in 466 (0.2 percent) in a 60-year-old woman [",
"      <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/24\">",
"       24",
"      </a>",
"      ]. Lifetime cancer risk estimates were lower in men: 1 in 686 (0.15 percent) in a 20-year-old man and 1 in 1241 (0.08 percent) for a 60-year-old man.",
"     </li>",
"     <li>",
"      A table of age-, sex-, and radiation exposure dose-specific estimates for LAR of cancer for a single 64-slice CCTA was developed based upon scanner data from 561 patients (",
"      <a class=\"graphic graphic_table graphicRef52649 \" href=\"UTD.htm?41/10/42158\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It may be helpful for healthcare providers discussing these issues with patients to put these potential risks in perspective relative to risks in everyday life. The following table provides a synopsis of the potential risk of dying from cancer at different levels of radiation dose and the odds of dying attributable to difficult-to-avoid environmental circumstances or common daily activities (",
"    <a class=\"graphic graphic_table graphicRef81942 \" href=\"UTD.htm?26/34/27181\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     BALANCING RISKS AND BENEFITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential risks of tests that use ionizing radiation must be weighed against the potential benefits of these tests. This assessment is difficult since the health risks related to radiation exposure at the levels common in cardiovascular imaging are controversial. In addition, evidence is limited on the impact of these tests on clinical outcomes.",
"   </p>",
"   <p>",
"    Acknowledging these limitations, an individualized assessment of potential risks and benefits of each imaging procedure is required that incorporates the patient's age and gender, clinical presentation, the health risks implied by the tentative diagnosis for which imaging is to be performed, and the types of imaging modalities that are appropriate to address the clinical question at hand.",
"   </p>",
"   <p>",
"    As an example, CCTA or radionuclide myocardial perfusion stress testing in a 65-year-old symptomatic man whose chest pain is at intermediate probability of being due to ischemic heart disease, the benefit of identifying treatable, potentially life-threatening coronary artery disease would generally be considered as outweighing the potential risk of imaging associated radiation. This is true given the probability of morbidity and mortality from undiagnosed cardiovascular disease in such an individual before a potential radiation-induced cancer could emerge as a clinical problem. In contrast, CCTA to assess prognosis in an asymptomatic 40-year-old woman by identifying or excluding the presence of subclinical coronary artery plaques (\"screening\") is not proven to improve quality of life or longevity. In this situation, the potential risk would likely outweigh the potential benefit. The risk-benefit of such screening examination might require re-evaluation in the future if coronary CT examinations at very low doses (&lt;3 mSv) became available and if a clinical benefit of such screening was demonstrated by outcomes data.",
"   </p>",
"   <p>",
"    Although, the health risks related to radiation exposure at the levels common in cardiovascular imaging are controversial, it is prudent to follow the principles of performing only clinically appropriate tests and if testing is indicated, keeping the patient dose \"as low as reasonably achievable\" (ALARA). A 2009 science advisory on ionizing radiation in cardiac imaging from the American Heart Association offered the following recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14376/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac imaging studies that expose patients to ionizing radiation should only be ordered after individualized assessment of risks and benefits to the patient, and in accordance with established appropriateness criteria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      It is important to consider the risk of missing an important diagnosis if imaging is not performed because of concerns about radiation exposure.",
"     </li>",
"     <li>",
"      Among equivalent tests, the one that exposes that patient to the least amount of radiation should be chosen.",
"     </li>",
"     <li>",
"      Among younger patients, imaging modalities without radiation exposure should be preferred if possible (for example, MR coronary angiography over coronary CT angiography if a congenital coronary anomaly is to be excluded or defined, or stress echocardiography instead of radionuclide myocardial perfusion imaging in patients with chest pain).",
"     </li>",
"     <li>",
"      Potential risks and benefits of the imaging study being considered should be discussed with the patient whenever practical and appropriate.",
"     </li>",
"     <li>",
"      Every effort should be made to avoid needlessly repeating imaging studies that use ionizing radiation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once it has been established that a cardiac imaging test that uses ionizing radiation is needed, the test should be performed with every effort to reduce patient dose as much as possible without jeopardizing the diagnostic quality of the exam.",
"     </li>",
"     <li>",
"      Routine surveillance radionuclide stress tests or cardiac CTs in asymptomatic patients at low risk for ischemic heart disease are NOT recommended",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiation dosimetry reference values are useful for quality control and benchmarking among institutions. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Parameters'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The effective dose (E) is a broad estimate of the risk of biologic detriment from a partial body exposure to ionizing radiation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Parameters'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The collective medical radiation dose to the US population has increased more than sevenfold since the early 1980s, largely related to computed tomography and nuclear medicine studies. The annual total radiation exposure to individuals who are NOT exposed to",
"      <strong>",
"       medical",
"      </strong>",
"      ionizing radiation has generally changed only modestly since 1982. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Determinants of radiation dose from fluoroscopy include patient habitus (greater for obese patients), operator technique and procedural complexity (which impact exposure time), the x-ray system, and selected settings. Substantial variation in fluoroscopic exposure rates among cardiac catheterization laboratories has been observed. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Radiation dose and determinants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Effective radiation doses from CT imaging vary with equipment, patient size, body parts imaged, and imaging protocols. Several strategies are available for reducing radiation dose and these do not necessitate a reduction in image quality. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Options for reducing radiation dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In radionuclide imaging, the choice of the radiopharmaceutical, individualized adjustment of injected activity, use of sensitive equipment and improved reconstruction algorithms, and use of stress-only protocols are options for reducing radiation dose.",
"     </li>",
"     <li>",
"      Prolonged fluoroscopic exposure (generally greater than 60 minutes) can cause skin burns. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Health risks of radiation exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of radiation-induced carcinogenesis from medical imaging is controversial. Estimates of potential cancer risk from cardiovascular imaging are based on a linear no-threshold model, which, while unproven, is the model best supported by the currently-available epidemiological data. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Potential carcinogenesis from imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac imaging studies that expose patients to ionizing radiation should only be ordered after individualized assessment of risks and benefits to the patient, and in accordance with established appropriateness criteria. Among equivalent options, the one that exposes that patient to the least amount of radiation should be chosen. The selection of an alternative test that involves no ionizing radiation, such as echocardiography or magnetic resonance imaging, should be considered. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Balancing risks and benefits'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/1\">",
"      Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 2007; 357:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/2\">",
"      Fazel R, Krumholz HM, Wang Y, et al. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med 2009; 361:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/3\">",
"      Morin RL, Gerber TC, McCollough CH. Radiation dose in computed tomography of the heart. Circulation 2003; 107:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/4\">",
"      Einstein AJ, Moser KW, Thompson RC, et al. Radiation dose to patients from cardiac diagnostic imaging. Circulation 2007; 116:1290.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Radiology (ACR) practice guideline for diagnostic reference levels in medical x-ray imaging. 2006. file://www.acr.org/SecondaryMainMenuCategories/quality_safety/RadSafety/RadiationSafety/guideline-diagnostic-reference.aspx (Accessed on March 12, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/6\">",
"      Suleiman OH, Conway BJ, Quinn P, et al. Nationwide survey of fluoroscopy: radiation dose and image quality. Radiology 1997; 203:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/7\">",
"      Van Unnik JG, Broerse JJ, Geleijns J, et al. Survey of CT techniques and absorbed dose in various Dutch hospitals. Br J Radiol 1997; 70:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/8\">",
"      McCollough CH, Schueler BA. Calculation of effective dose. Med Phys 2000; 27:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/9\">",
"      Martin CJ. Effective dose: how should it be applied to medical exposures? Br J Radiol 2007; 80:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/10\">",
"      Gerber TC, Carr JJ, Arai AE, et al. Ionizing radiation in cardiac imaging: a science advisory from the American Heart Association Committee on Cardiac Imaging of the Council on Clinical Cardiology and Committee on Cardiovascular Imaging and Intervention of the Council on Cardiovascular Radiology and Intervention. Circulation 2009; 119:1056.",
"     </a>",
"    </li>",
"    <li>",
"     International Atomic Energy Agency (IAEA)'s Smart Card project. file://rpop.iaea.org/RPOP/RPoP/Content/Documents/Whitepapers/smart-card-article.pdf (Accessed on December 07, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/12\">",
"      Mettler FA Jr, Thomadsen BR, Bhargavan M, et al. Medical radiation exposure in the U.S. in 2006: preliminary results. Health Phys 2008; 95:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/13\">",
"      Schauer DA, Linton OW. NCRP Report No. 160, Ionizing Radiation Exposure of the Population of the United States, medical exposure--are we doing less with more, and is there a role for health physicists? Health Phys 2009; 97:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/14\">",
"      Chen J, Einstein AJ, Fazel R, et al. Cumulative exposure to ionizing radiation from diagnostic and therapeutic cardiac imaging procedures: a population-based analysis. J Am Coll Cardiol 2010; 56:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/15\">",
"      Laskey WK, Wondrow M, Holmes DR Jr. Variability in fluoroscopic X-ray exposure in contemporary cardiac catheterization laboratories. J Am Coll Cardiol 2006; 48:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/16\">",
"      Cusma JT, Bell MR, Wondrow MA, et al. Real-time measurement of radiation exposure to patients during diagnostic coronary angiography and percutaneous interventional procedures. J Am Coll Cardiol 1999; 33:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/17\">",
"      Perisinakis K, Damilakis J, Theocharopoulos N, et al. Accurate assessment of patient effective radiation dose and associated detriment risk from radiofrequency catheter ablation procedures. Circulation 2001; 104:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/18\">",
"      Macle L, Weerasooriya R, Jais P, et al. Radiation exposure during radiofrequency catheter ablation for atrial fibrillation. Pacing Clin Electrophysiol 2003; 26:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/19\">",
"      Lickfett L, Mahesh M, Vasamreddy C, et al. Radiation exposure during catheter ablation of atrial fibrillation. Circulation 2004; 110:3003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/20\">",
"      Ector J, Dragusin O, Adriaenssens B, et al. Obesity is a major determinant of radiation dose in patients undergoing pulmonary vein isolation for atrial fibrillation. J Am Coll Cardiol 2007; 50:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/21\">",
"      Smith-Bindman R, Lipson J, Marcus R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med 2009; 169:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/22\">",
"      Hausleiter J, Meyer T, Hermann F, et al. Estimated radiation dose associated with cardiac CT angiography. JAMA 2009; 301:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/23\">",
"      Einstein AJ, Weiner SD, Bernheim A, et al. Multiple testing, cumulative radiation dose, and clinical indications in patients undergoing myocardial perfusion imaging. JAMA 2010; 304:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/24\">",
"      Einstein AJ, Henzlova MJ, Rajagopalan S. Estimating risk of cancer associated with radiation exposure from 64-slice computed tomography coronary angiography. JAMA 2007; 298:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/25\">",
"      McCollough CH, Primak AN, Saba O, et al. Dose performance of a 64-channel dual-source CT scanner. Radiology 2007; 243:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/26\">",
"      Earls JP, Berman EL, Urban BA, et al. Prospectively gated transverse coronary CT angiography versus retrospectively gated helical technique: improved image quality and reduced radiation dose. Radiology 2008; 246:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/27\">",
"      Raff GL, Chinnaiyan KM, Share DA, et al. Radiation dose from cardiac computed tomography before and after implementation of radiation dose-reduction techniques. JAMA 2009; 301:2340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/28\">",
"      Maruyama T, Takada M, Hasuike T, et al. Radiation dose reduction and coronary assessability of prospective electrocardiogram-gated computed tomography coronary angiography: comparison with retrospective electrocardiogram-gated helical scan. J Am Coll Cardiol 2008; 52:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/29\">",
"      Pontone G, Andreini D, Bartorelli AL, et al. Diagnostic accuracy of coronary computed tomography angiography: a comparison between prospective and retrospective electrocardiogram triggering. J Am Coll Cardiol 2009; 54:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/30\">",
"      Rosenthal LS, Mahesh M, Beck TJ, et al. Predictors of fluoroscopy time and estimated radiation exposure during radiofrequency catheter ablation procedures. Am J Cardiol 1998; 82:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/31\">",
"      Koenig TR, Mettler FA, Wagner LK. Skin injuries from fluoroscopically guided procedures: part 2, review of 73 cases and recommendations for minimizing dose delivered to patient. AJR Am J Roentgenol 2001; 177:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/32\">",
"      Koenig TR, Wolff D, Mettler FA, Wagner LK. Skin injuries from fluoroscopically guided procedures: part 1, characteristics of radiation injury. AJR Am J Roentgenol 2001; 177:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/33\">",
"      Einstein AJ. Effects of radiation exposure from cardiac imaging: how good are the data? J Am Coll Cardiol 2012; 59:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/34\">",
"      Pearce MS, Salotti JA, Little MP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet 2012; 380:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/35\">",
"      Einstein AJ. Beyond the bombs: cancer risks of low-dose medical radiation. Lancet 2012; 380:455.",
"     </a>",
"    </li>",
"    <li>",
"     Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation Board on Radiation Effects Research Division on Earth and Life Studies National Research Council of the National Academies. Health risks from exposure to low levels of ionizing radiation: BEIR VII-Phase 2. National Academies Press; Washington, DC 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/37\">",
"      Tubiana M, Feinendegen LE, Yang C, Kaminski JM. The linear no-threshold relationship is inconsistent with radiation biologic and experimental data. Radiology 2009; 251:13.",
"     </a>",
"    </li>",
"    <li>",
"     National Council on Radiation Protection and Measurements (NCRP). Risk estimates for radiation protection. National Council on Radiation Protection and Measurements (NCRP), Bethesda, MD 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/39\">",
"      Berrington de Gonz&aacute;lez A, Darby S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet 2004; 363:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14376/abstract/40\">",
"      Faletra FF, D'Angeli I, Klersy C, et al. Estimates of lifetime attributable risk of cancer after a single radiation exposure from 64-slice computed tomographic coronary angiography. Heart 2010; 96:927.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5325 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.147-60A40F9FB9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_2_14376=[""].join("\n");
var outline_f14_2_14376=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RADIATION DOSIMETRY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Parameters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Radiation doses associated with medical imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Radiation dose and determinants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6237370\">",
"      - Multiple testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Options for reducing radiation dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HEALTH RISKS OF RADIATION EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Potential carcinogenesis from imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      BALANCING RISKS AND BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5325\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5325|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/60/5069\" title=\"table 1\">",
"      Effective dose estimates for imaging tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/41/16030\" title=\"table 2\">",
"      Estimates of effective doses of standard MPI protocols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/10/42158\" title=\"table 3\">",
"      LAR of all cancer from a 64-slice CCTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/34/27181\" title=\"table 4\">",
"      Risks of malignancy or death from radiation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4106?source=related_link\">",
"      Biology and clinical features of radiation injury in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17689?source=related_link\">",
"      Clinical features of radiation exposure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_2_14377="Diagnosis of celiac disease";
var content_f14_2_14377=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of celiac disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/2/14377/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/2/14377/contributors\">",
"     Ciar&aacute;n P Kelly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/2/14377/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/2/14377/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/2/14377/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/2/14377/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/2/14377/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease can be defined as a small bowel disorder characterized by mucosal inflammation, villous atrophy, and crypt hyperplasia, which occur upon exposure to dietary gluten and which demonstrate improvement after withdrawal of gluten from the diet. However, the availability of serologic testing for celiac disease and the common use of upper endoscopy has complicated the definition, since these tests have identified patients who appear to have the disease but have variable degrees of histopathologic changes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms. Thus, several categories of celiac disease have emerged. Whether these phenotypes are clinically useful remains to be determined [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history of these various forms of celiac disease is incompletely understood. In particular, the long-term risk of complications in patients who are asymptomatic is unclear. Such patients may also be least likely to comply with a gluten-free diet. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=see_link\">",
"     \"Management of celiac disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will focus on the use of serum antibodies in the diagnosis and management of celiac disease. This topic is also discussed in guidelines issued by several organizations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The recommendations in this topic are largely consistent with a 2004 consensus statement from the National Institutes of Health (NIH) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WHO SHOULD BE TESTED",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for celiac disease should be considered in the following groups of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those with gastrointestinal symptoms including chronic or recurrent diarrhea, malabsorption, weight loss, and abdominal distension or bloating. This includes patients with symptoms suggestive for irritable bowel syndrome or severe lactose intolerance.",
"     </li>",
"     <li>",
"      Individuals without other explanations for signs and symptoms such as iron deficiency anemia, folate or vitamin B12 deficiency, persistent elevation in serum aminotransferases, short stature, delayed puberty, recurrent fetal loss, low birthweight infants, and reduced fertility persistent aphthous stomatitis, dental enamel hypoplasia, idiopathic peripheral neuropathy, nonhereditary cerebellar ataxia, or recurrent migraine headaches.",
"     </li>",
"     <li>",
"      Symptomatic individuals at high risk for celiac disease including patients with type 1 diabetes mellitus or other autoimmune disorders, first- and second-degree relatives of individuals with celiac disease, patients with Turner, Down, or Williams syndromes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As will be discussed below, screening of the general population is not recommended. Screening of patients with osteoporosis is also not recommended in the consensus statement since the prevalence of celiac disease is not significantly increased among the general population of patients with osteoporosis.",
"   </p>",
"   <p>",
"    However, this conclusion was not supported by a study published after the consensus conference in which the prevalence of celiac disease in 260 men and women with osteoporosis was compared with 575 controls without osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/6\">",
"     6",
"    </a>",
"    ]. The prevalence of biopsy proven celiac disease was significantly higher in the osteoporosis group (3.4 versus 0.2 percent). Most patients had biochemically evident secondary hyperparathyroidism with vitamin D deficiency. Furthermore, all but one had other clinical features suggestive of celiac disease including anemia, weight loss, or gastrointestinal symptoms. Thus, until further data are available, screening patients with osteoporosis for celiac disease should probably be confined to those with additional clinical or laboratory features suggestive of the disorder and those with known risk factors for celiac disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;An approach to diagnosis of celiac disease is summarized in the following algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef62181 \" href=\"UTD.htm?22/45/23250\">",
"     algorithm 1",
"    </a>",
"    ). All testing should be performed while patients are on a gluten-rich diet. No single test can confidently establish the diagnosis of celiac disease in every individual. As a result, the most important initial step in diagnosis is recognition of the many clinical features that can be associated with the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Serologic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general rule, testing should begin with serologic evaluation. As will be discussed below, the most sensitive and specific tests are IgA anti tissue transglutaminase (anti-tTG) and IgA endomysial antibody, which have equivalent diagnostic accuracy.",
"   </p>",
"   <p>",
"    By contrast, antigliadin antibody tests are no longer used routinely because of their lower sensitivity and specificity. However, a second generation AGA test (Deamidated Gliadin Peptide [DGP]) yielded far higher diagnostic accuracy (sensitivity 94 percent, specificity 99 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The DGP uses synthetic gliadin peptides that mimic tTG-modified gliadin sequences to capture serum IgA or IgG against DGP. If these initial data are reproducible in practice, the combination of anti-tTG and DGP serology may become a powerful non-invasive pairing for serologic diagnosis of celiac disease. Serologic testing may not be as accurate in children less than age five and is less accurate before age two.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Testing on a gluten-free diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;An approach to diagnosis of celiac disease in patients on a gluten-free diet is summarized in the following algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef85570 \" href=\"UTD.htm?22/35/23102\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/9\">",
"     9",
"    </a>",
"    ]. Baseline antibody testing (anti-tTG or IgA endomysial antibody and anti-DGP [if available]) should be performed in patients on a gluten-free diet. Patients with positive serology should undergo a small bowel biopsy (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Small bowel biopsy'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Patients with negative serologies should undergo HLA",
"    <span class=\"nowrap\">",
"     DQ2/DQ8",
"    </span>",
"    testing to determine if the patient is genetically susceptible to celiac disease. If HLA",
"    <span class=\"nowrap\">",
"     DQ2/DQ8",
"    </span>",
"    testing is negative, celiac disease is excluded.",
"   </p>",
"   <p>",
"    Patients who are positive for HLA",
"    <span class=\"nowrap\">",
"     DQ2/DQ8",
"    </span>",
"    should undergo a modified gluten challenge (3 g",
"    <span class=\"nowrap\">",
"     gluten/day",
"    </span>",
"    for two weeks) and, if tolerated, a full gluten challenge (3 g",
"    <span class=\"nowrap\">",
"     gluten/day",
"    </span>",
"    for eight weeks) followed by a duodenal biopsy. Serology (anti-tTG or IgA endomysial antibody and anti-DGP) should be checked at the end of the full gluten challenge and, if negative, serology should be repeated in two to eight weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Small bowel biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a positive IgA endomysial or transglutaminase antibody test should undergo an upper endoscopy with small bowel biopsy. Exceptions are those who have biopsy-proven dermatitis herpetiformis in whom the diagnosis can be established without a small bowel biopsy.",
"   </p>",
"   <p>",
"    Multiple biopsies should be obtained from the duodenal bulb and the second and third portion of the duodenum [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Duodenal bulb biopsies should be clearly labeled as such to help ensure that the pathologist takes into account the different mucosal architecture of the bulb to avoid false positive reports of villous atrophy. The exact minimal number of duodenal biopsies needed to make a diagnosis of celiac disease is uncertain, although some experts believe that at least four to six should be obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/3,12,13\">",
"     3,12,13",
"    </a>",
"    ]. The duodenal mucosa may appear atrophic with loss of folds, contain visible fissures, have a nodular appearance or the folds may be scalloped (",
"    <a class=\"graphic graphic_picture graphicRef65969 \" href=\"UTD.htm?11/1/11281\">",
"     picture 1",
"    </a>",
"    ), but such findings are not universally present and may be seen with other disorders (",
"    <a class=\"graphic graphic_table graphicRef60030 \" href=\"UTD.htm?16/1/16411\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/14\">",
"     14",
"    </a>",
"    ]. Staining techniques and high resolution magnification endoscopy can help identify areas of villous atrophy for biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The histologic features range from a mild alteration characterized only by increased intraepithelial lymphocytes, to a flat mucosa with total mucosal atrophy, complete loss of villi, enhanced epithelial apoptosis, and crypt hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/18-23\">",
"     18-23",
"    </a>",
"    ]. The histologic findings in celiac disease can be described using the Marsh-Oberhuber classification [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Marsh 0 (preinfiltrative): less than 30 intraepithelial lymphocytes (IELs) per 100 enterocytes, normal villi and crypts. This finding represents to normal histology.",
"     </li>",
"     <li>",
"      Marsh 1 (infiltrative): more than 30 IELs per 100 enterocytes, normal villi and crypts. This finding is nonspecific and can occur in early or mild celiac disease, but it may also be seen in healthy individuals, in patients with small intestinal bacterial overgrowth, in Crohn&rsquo;s disease, in other autoimmune disorders, in patients infected with Helicobacter pylori, in patients taking nonsteroidal antiinflammatory drugs, and in a variety of other situations.",
"     </li>",
"     <li>",
"      Marsh 2 (infiltrative-hyperplastic): more than 30 IELs per 100 enterocytes, normal villi, crypt hyperplasia",
"     </li>",
"     <li>",
"      Marsh 3a (flat destructive): more than 30 IELs per 100 enterocytes, mild villous atrophy, crypt hyperplasia",
"     </li>",
"     <li>",
"      Marsh 3b (flat destructive): more than 30 IELs per 100 enterocytes, moderate villous atrophy, crypt hyperplasia",
"     </li>",
"     <li>",
"      Marsh 3c (flat destructive): more than 30 IELs per 100 enterocytes, total villous atrophy, crypt hyperplasia",
"     </li>",
"     <li>",
"      Marsh 4 (atrophic-hypoplastic): more than 30 IELs per 100 enterocytes, total villous atrophy, crypt hypoplasia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis is presumptively established when there is concordance between the serologic results and the biopsy findings. It is confirmed when symptoms resolve subsequently on a gluten-free diet. Demonstration of histologic normalization is not always required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Suggestive clinical features but negative serologic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four main possibilities in those with suggestive clinical features but negative serologic tests:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The individual may have selective IgA deficiency. In such patients, testing for IgG deamidated gliadin peptide antibodies, IgG anti tissue transglutaminase antibodies,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      IgG endomysial antibodies should be performed.",
"     </li>",
"     <li>",
"      The individual may already be on a low gluten diet. An approach to diagnosis of celiac disease in patients on a gluten-free diet is summarized in the following algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef85570 \" href=\"UTD.htm?22/35/23102\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Testing on a gluten-free diet'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The serologic test could be falsely negative in which case a small bowel biopsy is needed to make a diagnosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Small bowel biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient may not have celiac disease in which case other causes of symptoms (eg, wheat allergy or nonceliac gluten sensitivity) or villous atrophy should be considered (",
"      <a class=\"graphic graphic_table graphicRef60030 \" href=\"UTD.htm?16/1/16411\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef61019 \" href=\"UTD.htm?42/57/43934\">",
"       algorithm 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/25-27\">",
"       25-27",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Patients with a wheat allergy have negative celiac serologies and normal duodenal biopsies, but an IgE serology and skin prick test to wheat are positive. Patients with nonceliac gluten sensitivity have negative celiac serologies, normal or near normal duodenal biopsies, and negative IgE serology and skin prick test to wheat. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2042?source=see_link&amp;anchor=H11#H11\">",
"       \"Food allergens: Overview of clinical features and cross-reactivity\", section on 'Grains'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are occasional patients in whom the diagnosis is unclear despite the above. Such patients can undergo testing for HLA haplotypes associated with celiac disease. More than 99 percent of patients with celiac disease have HLA DQ2",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    DQ8 compared with about 40 percent of the general population. Thus, celiac disease is highly unlikely in patients without these haplotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Positive serologic tests but negative small bowel biopsies",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgA tTG serology may occasionally be positive but the small intestinal biopsy normal. False positive tTG results are rare but do occur and are usually low titer (typically less than twice the upper limit of normal). Repeating the test using an assay that uses human tTG as the capture antigen may resolve the discrepancy since older tTG tests using non-human tTG have more frequently been associated with false positive results. The intestinal biopsy should be reviewed by a pathologist familiar with CD to look for subtle abnormalities of CD such as an increase in IELs. If these two steps do not reconcile the results, the patient can be placed on a high gluten diet and, after 6 to 12 weeks, numerous additional biopsies obtained from multiple sites in the mid and distal duodenum since CD enteropathy can be patchy and missed due to sampling error. As noted above, staining techniques and high resolution magnification endoscopy can help identify areas of villous atrophy for biopsy.",
"   </p>",
"   <p>",
"    Some patients have a positive serologic test and only mild histologic changes supportive of celiac disease. Patients with mild villous atrophy appear to benefit from a gluten-free diet. The response to gluten-free diet in patients with an increase in intraepithelial lymphocytes but normal villi is less clear [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There may be a subset of patients with clinical features resembling IBS who do not have a serologic or histologic profile diagnostic of celiac disease but who may respond symptomatically to a gluten-free diet. One study suggested that the presence of serum IgG antigliadin antibodies and expression of HLA-DQ2 may be predictive of such a response in patients with diarrhea-predominant IBS but the strength of the association remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SERUM ANTIBODY ASSAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of serologic studies have been described to aid in the diagnosis of celiac disease, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      IgA endomysial antibody (IgA EMA)",
"     </li>",
"     <li>",
"      IgA tissue transglutaminase antibody (IgA tTG)",
"     </li>",
"     <li>",
"      IgA antigliadin antibody (IgA AGA)",
"     </li>",
"     <li>",
"      IgG antigliadin antibody (IgG AGA)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum IgA endomysial and tissue transglutaminase antibody testing have the highest diagnostic accuracy. The IgA and IgG antigliadin antibody tests have lower diagnostic accuracy with frequent false positive results and are therefore no longer recommended for initial diagnostic evaluation or screening [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the newer anti-deamidated gliadin peptide assays described above may result in the re-introduction of AGA testing in celiac disease. IgA EMA, IgA tTG, and IgA AGA levels fall with treatment; as a result, these assays can be used as a noninvasive means of monitoring the response to a gluten-free diet (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Monitoring adherence and response to gluten-free diet'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Serologic studies for celiac disease can be divided into two groups based upon their target antigens: antiendomysial and antigliadin antibody tests [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     IgA endomysial assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endomysial antibodies bind to connective tissue surrounding smooth muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/31-38\">",
"     31-38",
"    </a>",
"    ]. Frozen sections of monkey esophagus were initially used for the assay. Currently, many laboratories use sections of human umbilical cord which are more readily available [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Serum IgA endomysial antibodies bind to the endomysium, producing a characteristic staining pattern, which is visualized by indirect immunofluorescence [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. The test result is reported simply as positive or negative since even low titers of serum IgA endomysial antibodies are specific for celiac disease. The target antigen has been identified as a tissue transglutaminase (see below).",
"   </p>",
"   <p>",
"    IgA endomysial antibody testing is moderately sensitive and highly specific for untreated celiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/31-35,37,38\">",
"     31-35,37,38",
"    </a>",
"    ]. Serum levels of IgA endomysial antibody fall on a gluten-free diet and the test often becomes negative in treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Anti-tissue transglutaminase antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antigen against which antiendomysial antibodies are directed is a tissue transglutaminase (tTG) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/43\">",
"     43",
"    </a>",
"    ]. Anti-tTG antibodies were highly sensitive and specific for the diagnosis of celiac disease in most reports [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/44-48\">",
"     44-48",
"    </a>",
"    ]. In an illustrative series, anti-tTG antibodies were present in 98 percent of patients with biopsy-proven celiac disease compared to 5 percent of controls [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/44\">",
"     44",
"    </a>",
"    ]. In another study that included 136 patients with celiac disease and 207 controls, the sensitivity and specificity of anti-tTG antibodies was 95 and 94 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ELISA tests for IgA anti-tTG antibodies are now widely available and are easier to perform and less costly than the immunofluorescence assay used to detect IgA endomysial antibodies. The diagnostic accuracy of IgA anti-tTG immunoassays has been improved further by the use of human tTG in place of the non-human tTG preparations used in earlier immunoassay kits [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Antigliadin antibody assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gliadin is a component of the wheat storage protein gluten. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    .) Purified gliadin is readily available and is used as the antigen for enzyme-linked immunosorbent assays (ELISA) to detect serum antigliadin antibodies.",
"   </p>",
"   <p>",
"    Serum antigliadin antibody levels are frequently elevated in untreated celiac disease, and antigliadin assays have been used for some years as a diagnostic aid [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/31,32,34,50-59\">",
"     31,32,34,50-59",
"    </a>",
"    ]. Although these tests demonstrate moderate sensitivity and specificity, with the IgA tests being marginally superior, their positive predictive value in a general population is relatively poor. In one series, as an example, the positive predictive value for IgG antigliadin antibodies corrected for the expected prevalence in the general population was &lt;2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antigliadin antibody test results are reported as a titer or level. A high titer of antigliadin antibody is somewhat more specific for celiac disease than a low titer, but some normal individuals have high serum levels of antigliadin antibody. Antigliadin antibody levels decrease during treatment with a gluten-free diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Assay sensitivity and specificity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of the literature estimated that the sensitivity and specificity of IgA endomysial and IgA tissue transglutaminase antibodies were over 95 percent and close to 100 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the literature reports wide variations in test sensitivity and specificity among different laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/31,61\">",
"     31,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is therefore important to know the sensitivity and specificity of the assay as performed by the testing laboratory before determining the clinical significance of a particular test result [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/62\">",
"     62",
"    </a>",
"    ]. The following data come from our experience [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      IgA endomysial antibodies &ndash; sensitivity 85 to 98 percent; specificity 97 to 100 percent",
"     </li>",
"     <li>",
"      IgA tissue transglutaminase antibodies &ndash; sensitivity 90 to 98 percent; specificity 95 to 97 percent",
"     </li>",
"     <li>",
"      IgA antigliadin antibodies &ndash; sensitivity 80 to 90 percent; specificity 85 to 95 percent",
"     </li>",
"     <li>",
"      IgG antigliadin antibodies &ndash; sensitivity 75 to 85 percent; specificity 75 to 90 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is also important to consider the likelihood that the patient has the disease since, at a given sensitivity and specificity, the pretest probability of disease determines the positive and negative predictive values of the test (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Clinical application of serologic tests'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    In addition to laboratory variation, the sensitivity of these tests may depend upon the severity of the disease. In one report, as an example, serum antibodies were determined in 101 patients with biopsy proven celiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/63\">",
"     63",
"    </a>",
"    ]. The sensitivity of IgA endomysial antibodies varied for 100 percent in patients with total villous atrophy to only 31 percent in those with partial villous atrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Role of antibodies in disease pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antigliadin antibodies do",
"    <strong>",
"     not",
"    </strong>",
"    appear to be essential for the pathogenesis of celiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/31\">",
"     31",
"    </a>",
"    ]. Furthermore, many normal individuals have increased IgA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IgG antigliadin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/51,64\">",
"     51,64",
"    </a>",
"    ]. In contrast, IgA endomysial antibodies are rarely found in the absence of gluten-sensitive enteropathy. However, patients with celiac disease who lack these antibodies do not differ in their clinical presentation from those who are antibody positive. Nevertheless, there is some evidence to suggest that, in addition to cellular immunity, antibodies against tissue transglutaminase, the target autoantigen within the endomysium, are of some pathogenetic importance. Furthermore, tissue transglutaminase enzymatically alters gliadin peptides to increase their propensity to induce helper T-cell activation when presented by DQ2 or DQ8 on antigen presenting cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individuals with celiac disease also have increased levels of serum antibodies against other food proteins such as beta-lactoglobulin, casein, and ovalbumin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/65\">",
"     65",
"    </a>",
"    ]. It is not clear whether this reflects a general aberrant immune responsiveness to food antigens or results from enhanced systemic exposure to these proteins because of increased small intestinal permeability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CLINICAL APPLICATION OF SEROLOGIC TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three different clinical circumstances should be considered when using serologic studies in the diagnosis and management of celiac disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluation of individuals with a low pretest probability for celiac disease. Such patients may have undergone testing for celiac disease during evaluation of common disorders such as irritable bowel syndrome, reduced fertility or osteoporosis.",
"     </li>",
"     <li>",
"      Evaluation of individuals with a moderate or high pretest probability for celiac disease",
"     </li>",
"     <li>",
"      Monitoring adherence and response to a gluten-free diet",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Individuals with a low risk for celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the pretest probability of celiac disease is perceived to be low (ie, less than 5 percent), serologic studies are useful in excluding the diagnosis. Asymptomatic patients without a family history of celiac disease or laboratory or clinical evidence for malabsorption can be considered to be low risk. The patient's ethnicity may also help determine baseline risk. While celiac disease affects persons of many ethnic backgrounds, it is rare in those of purely Chinese, Japanese, or Sub-Saharan African descent.",
"   </p>",
"   <p>",
"    In the low-risk setting, the IgA endomysial antibody test has the highest diagnostic accuracy but is a little more costly than the IgA tTG ELISA test (",
"    <a class=\"graphic graphic_algorithm graphicRef62181 \" href=\"UTD.htm?22/45/23250\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/31,34\">",
"     31,34",
"    </a>",
"    ]. The antigliadin antibody tests have lower diagnostic accuracy.",
"   </p>",
"   <p>",
"    As noted above, the serum IgA tissue transglutaminase and IgA endomysial tests have similar sensitivities. A negative result for either test has a high negative predictive value in this situation and may obviate the need for small bowel biopsy.",
"   </p>",
"   <p>",
"    The IgG antigliadin test is less sensitive and therefore less useful. IgG antigliadin is usually positive in the 1 to 2 percent of celiac patients who have IgA deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Many clinicians test simultaneously for both IgA and IgG antigliadin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. This approach gives a small incremental increase in sensitivity but increases cost and leads to frequent false positive test results, especially with the IgG antigliadin test. As a result most experts advise against routine AGA testing. The newer DGP tests are more specific and may be used to supplement tTG testing. IgA tTG titers will be very low in patients with celiac disease and IgA deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/68\">",
"     68",
"    </a>",
"    ]. IgG DGP testing can be used in patients with IgA deficiency.",
"   </p>",
"   <p>",
"    The specificities of the IgA endomysial and IgA tissue transglutaminase tests are high. Thus, their positive predictive values are high even in low-risk populations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/34,35,38\">",
"     34,35,38",
"    </a>",
"    ]. In contrast, the specificities of IgA and IgG antigliadin tests are lower, and positive results have a low positive predictive value in low-risk populations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/35,64,69\">",
"     35,64,69",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Screening in asymptomatic individuals'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In summary, a positive IgA tissue transglutaminase or endomysial antibody test is highly specific (",
"    <a class=\"graphic graphic_algorithm graphicRef62181 \" href=\"UTD.htm?22/45/23250\">",
"     algorithm 1",
"    </a>",
"    ). The standard antigliadin antibody tests have lower diagnostic accuracy and are no longer recommended because they yield many false positive results (15 to 20 percent of subjects tested) leading to unnecessary endoscopy with biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Individuals with a moderate or high risk for celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the pretest probability of celiac disease is perceived to be high (ie, greater than 5 percent), diagnosis is based upon serologic tests and histology. Celiac disease is frequently associated with dermatitis herpetiformis, Down syndrome, selective IgA deficiency, and other conditions that have autoimmune features such as type 1 diabetes mellitus, thyroid disease, and autoimmune liver disease. Patients with these conditions or a family history of celiac disease can be considered as being at increased risk. Patients with suggestive clinical features such as severe diarrhea, weight loss, or persistent anemia can also be considered to be at high risk.",
"   </p>",
"   <p>",
"    The standard approach has been to obtain a small bowel biopsy for histopathologic examination. However, the very high specificity of the IgA endomysial test has led to debate as to whether a positive result in the appropriate clinical setting can be considered diagnostic and eliminate the need for small bowel biopsy. We recommend performing both IgA endomysial (or TTG) and small bowel biopsy prior to dietary treatment (",
"    <a class=\"graphic graphic_algorithm graphicRef62181 \" href=\"UTD.htm?22/45/23250\">",
"     algorithm 1",
"    </a>",
"    ). This approach provides the best means of making a definitive diagnosis of celiac disease from the outset.",
"   </p>",
"   <p>",
"    Antigliadin antibody tests are",
"    <strong>",
"     not",
"    </strong>",
"    helpful when there is a moderate or high probability of celiac disease. A positive or negative result will not alter the need for small bowel biopsy and definitive histologic diagnosis. Since antigliadin antibody tests have a high false positive rate there is no role for a trial of a gluten-free diet for presumed celiac disease based on the finding of an elevated antigliadin antibody level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Monitoring adherence and response to gluten-free diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic testing is also useful in monitoring the response to gluten-free diet. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of celiac disease in adults\", section on 'Monitoring the response to a gluten-free diet'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SCREENING IN ASYMPTOMATIC INDIVIDUALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening studies suggest that the incidence of celiac disease in whites of northern European ancestry may be as high as 1:100 to 1:250. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit of population screening for asymptomatic celiac disease, usually using the IgA endomysial or IgG tTG (transglutaminase) assays [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/35,38,51,64,70\">",
"     35,38,51,64,70",
"    </a>",
"    ], has not yet been demonstrated. The potential advantages of screening for asymptomatic celiac disease include a reduction in risk for enteropathy-associated T-cell lymphoma, a reversal of unrecognized nutritional deficiency states, resolution of mild or ignored intestinal symptoms, avoidance of other autoimmune disorders, an improvement in general well-being, and a possible reduction in mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These issues were addressed in a 2009 report from the Mayo Clinic in which serum was tested for endomysial antibodies and, if positive, for tTG in almost 22,000 individuals from different time periods [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/70\">",
"     70",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 9133 healthy young adults at an Air Force base in Minnesota in whom blood was obtained between 1948 and 1954, 14 (0.2 percent) had undiagnosed celiac disease. At a follow-up of 45 years, these individuals had a significant increase in mortality compared to those who were seronegative (hazard ratio 3.9).",
"     </li>",
"     <li>",
"      The rate of seropositivity was fourfold higher in samples obtained in a recent Olmsted County cohort matched for age or year of sampling. The rate of undiagnosed celiac disease was 4.0 to 4.5 times higher than in the original cohort (0.8 to 0.9 versus 0.2 percent), suggesting a dramatic increase in prevalence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The possible benefits of screening and subsequent therapy depend upon compliance with an exacting, sometimes expensive, dietary regimen. Asymptomatic individuals may not be sufficiently motivated to adhere to a strict gluten-free diet. There may also be adverse psychological effects when asymptomatic individuals receive a diagnosis of a chronic incurable condition that demands substantial lifestyle changes.",
"   </p>",
"   <p>",
"    For these reasons, widespread screening of asymptomatic individuals is not generally advocated at this time, even in populations in which the prevalence of celiac disease is high. This must be distinguished from testing to diagnose celiac disease in patients with subtle clinical manifestations in which instance the value of serologic tests as diagnostic aids is widely accepted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OTHER NONINVASIVE TESTS FOR THE DIAGNOSIS OF CELIAC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of hematologic and biochemical abnormalities may be found in individuals with untreated celiac disease including iron deficiency,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    deficiency, and vitamin D deficiency. These abnormalities reflect nutritional deficiency states secondary to enteropathy-induced malabsorption. Although relevant to patient evaluation and management, none is sufficiently sensitive or specific to serve as useful screening or diagnostic tools [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/54\">",
"     54",
"    </a>",
"    ]. An oral xylose",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    absorption test, fecal fat evaluation, small bowel radiographic study, or capsule endoscopy may also be abnormal in untreated celiac disease, but will not provide a specific diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HLA typing may be useful in patients who are already on a gluten-free diet without having achieved a firm diagnosis. Those without HLA DQ2 or DQ8 are very unlikely to have celiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/73\">",
"     73",
"    </a>",
"    ]. A systematic review of the literature estimated that testing for these haplotypes had a sensitivity of 90 to 95 percent but specificity was only around 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, the greatest value lies in its negative predictive value (ie, the disease is unlikely in those with a negative result). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/6/13410?source=see_link\">",
"       \"Patient information: Celiac disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/14/11492?source=see_link\">",
"       \"Patient information: Celiac disease in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/31/36339?source=see_link\">",
"       \"Patient information: Celiac disease in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An approach to diagnosis of celiac disease is summarized in the following algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef62181 \" href=\"UTD.htm?22/45/23250\">",
"       algorithm 1",
"      </a>",
"      ). For patients who are already on a gluten-free diet, an approach to diagnosis of celiac disease is summarized in the following algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef85570 \" href=\"UTD.htm?22/35/23102\">",
"       algorithm 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      IgA deficiency is more common in celiac disease (2 to 5 percent) than in the general population (&lt;0.5 percent). The IgA EMA and IgA tTG serology tests will be falsely negative in untreated celiac disease in patients with IgA deficiency. As a result, total serum IgA can be measured in addition to IgA EMA or IgA tTG especially when there is heightened clinical suspicion for celiac disease and IgA markers are negative. If total IgA levels are abnormally low, an IgG-based assay should be used to test for celiac disease. The IgG antigliadin assay has been traditionally used in this circumstance but is not ideal since it yields frequent false positive results. Thus, serum IgG tTG or IgG DGP tests are preferable. Negative results upon testing for HLA DQ2 or DQ8 can also help exclude the diagnosis in this setting. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Serum antibody assays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to serologic markers, the diagnosis usually requires a small bowel biopsy, which can be obtained during upper endoscopy. Exceptions are patients with compatible serologic findings and biopsy-proven dermatitis herpetiformis in whom the diagnosis can be established without a small bowel biopsy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Small bowel biopsy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      A hallmark on histology is the presence of villous atrophy. However, villous atrophy can be patchy, and may also be present in a variety of other disorders that should be considered in appropriate clinical settings (",
"      <a class=\"graphic graphic_table graphicRef60030 \" href=\"UTD.htm?16/1/16411\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/74\">",
"       74",
"      </a>",
"      ]. Four to six biopsies in the duodenal bulb and second and third portion of the duodenum should be obtained to maximize the likelihood of detecting villous atrophy. Duodenal bulb biopsies should be clearly labeled as such to help ensure that the pathologist takes into account the different mucosal architecture of the bulb to avoid false positive reports of villous atrophy. The accuracy of biopsies can be improved with staining techniques and magnification endoscopy; however, these approaches are not used routinely. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4248?source=see_link\">",
"       \"Magnification endoscopy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A few controversies remain regarding confirmation of the diagnosis. Some authorities recommend that a repeat small intestinal biopsy should be obtained 6 to 24 months after beginning a gluten-free diet to demonstrate histologic improvement. Some also recommended a repeat small bowel biopsy (after gluten rechallenge) following a gluten-free diet. We do not believe that these approaches are generally required unless the diagnosis remains uncertain based upon the serologic profile, histology and clinical response. Furthermore, these approaches are not recommended in a consensus statement issued by the NIH [",
"      <a class=\"abstract\" href=\"UTD.htm?14/2/14377/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=see_link\">",
"       \"Management of celiac disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rostom A, Dube C, Cranney A, et al. Celiac disease. Summary, evidence report/technology assessment No 104 (Prepared by the University of Ottawa Evidence-based Practice Center, under Contract, No. 290-02-0021), AHRQ publication No 04-E)29-1, Agency for Healthcare Research and Quality, Rockville, MD 2004.",
"    </li>",
"    <li>",
"     National Institutes of Health Consensus Development Conference Statement. Celiac Disease 2004. Available at: file://consensus.nih.gov/ (Accessed on October 25, 2004).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/3\">",
"      Ludvigsson JF, Leffler DA, Bai JC, et al. The Oslo definitions for coeliac disease and related terms. Gut 2013; 62:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/4\">",
"      AGA Institute. AGA Institute Medical Position Statement on the Diagnosis and Management of Celiac Disease. Gastroenterology 2006; 131:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/5\">",
"      Bai JC, Fried M, Corazza GR, et al. World gastroenterology organisation global guidelines on celiac disease. J Clin Gastroenterol 2013; 47:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/6\">",
"      Stenson WF, Newberry R, Lorenz R, et al. Increased prevalence of celiac disease and need for routine screening among patients with osteoporosis. Arch Intern Med 2005; 165:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/7\">",
"      Sugai E, V&aacute;zquez H, Nachman F, et al. Accuracy of testing for antibodies to synthetic gliadin-related peptides in celiac disease. Clin Gastroenterol Hepatol 2006; 4:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/8\">",
"      Prince HE. Evaluation of the INOVA diagnostics enzyme-linked immunosorbent assay kits for measuring serum immunoglobulin G (IgG) and IgA to deamidated gliadin peptides. Clin Vaccine Immunol 2006; 13:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/9\">",
"      Leffler D, Schuppan D, Pallav K, et al. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/10\">",
"      Evans KE, Aziz I, Cross SS, et al. A prospective study of duodenal bulb biopsy in newly diagnosed and established adult celiac disease. Am J Gastroenterol 2011; 106:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/11\">",
"      Kurien M, Evans KE, Hopper AD, et al. Duodenal bulb biopsies for diagnosing adult celiac disease: is there an optimal biopsy site? Gastrointest Endosc 2012; 75:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/12\">",
"      Green PH, Cellier C. Celiac disease. N Engl J Med 2007; 357:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/13\">",
"      Pais WP, Duerksen DR, Pettigrew NM, Bernstein CN. How many duodenal biopsy specimens are required to make a diagnosis of celiac disease? Gastrointest Endosc 2008; 67:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/14\">",
"      Shah VH, Rotterdam H, Kotler DP, et al. All that scallops is not celiac disease. Gastrointest Endosc 2000; 51:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/15\">",
"      Cammarota G, Martino A, Pirozzi GA, et al. Direct visualization of intestinal villi by high-resolution magnifying upper endoscopy: a validation study. Gastrointest Endosc 2004; 60:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/16\">",
"      Hurlstone DP, Sanders DS. High-magnification immersion chromoscopic duodenoscopy permits visualization of patchy atrophy in celiac disease: an opportunity to target biopsies of abnormal mucosa. Gastrointest Endosc 2003; 58:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/17\">",
"      Lo A, Guelrud M, Essenfeld H, Bonis P. Classification of villous atrophy with enhanced magnification endoscopy in patients with celiac disease and tropical sprue. Gastrointest Endosc 2007; 66:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/18\">",
"      RUBIN CE, BRANDBORG LL, PHELPS PC, TAYLOR HC Jr. Studies of celiac disease. I. The apparent identical and specific nature of the duodenal and proximal jejunal lesion in celiac disease and idiopathic sprue. Gastroenterology 1960; 38:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/19\">",
"      Fry L, Seah PP, McMinn RM, Hoffbrand AV. Lymphocytic infiltration of epithelium in diagnosis of gluten-sensitive enteropathy. Br Med J 1972; 3:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/20\">",
"      Marsh MN. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). Gastroenterology 1992; 102:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/21\">",
"      Marsh MN, Crowe PT. Morphology of the mucosal lesion in gluten sensitivity. Baillieres Clin Gastroenterol 1995; 9:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/22\">",
"      Ferguson A, Arranz E, O'Mahony S. Clinical and pathological spectrum of coeliac disease--active, silent, latent, potential. Gut 1993; 34:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/23\">",
"      Troncone R, Greco L, Mayer M, et al. Latent and potential coeliac disease. Acta Paediatr Suppl 1996; 412:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/24\">",
"      Oberhuber G, Granditsch G, Vogelsang H. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol 1999; 11:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/25\">",
"      Carroccio A, Mansueto P, Iacono G, et al. Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity. Am J Gastroenterol 2012; 107:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/26\">",
"      Sanders DS, Aziz I. Non-celiac wheat sensitivity: separating the wheat from the chat! Am J Gastroenterol 2012; 107:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/27\">",
"      Biesiekierski JR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011; 106:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/28\">",
"      Hadithi M, von Blomberg BM, Crusius JB, et al. Accuracy of serologic tests and HLA-DQ typing for diagnosing celiac disease. Ann Intern Med 2007; 147:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/29\">",
"      Kurppa K, Collin P, Viljamaa M, et al. Diagnosing mild enteropathy celiac disease: a randomized, controlled clinical study. Gastroenterology 2009; 136:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/30\">",
"      Wahnschaffe U, Schulzke JD, Zeitz M, Ullrich R. Predictors of clinical response to gluten-free diet in patients diagnosed with diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2007; 5:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/31\">",
"      M&auml;ki M. The humoral immune system in coeliac disease. Baillieres Clin Gastroenterol 1995; 9:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/32\">",
"      B&uuml;rgin-Wolff A, Gaze H, Hadziselimovic F, et al. Antigliadin and antiendomysium antibody determination for coeliac disease. Arch Dis Child 1991; 66:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/33\">",
"      Chorzelski TP, Beutner EH, Sulej J, et al. IgA anti-endomysium antibody. A new immunological marker of dermatitis herpetiformis and coeliac disease. Br J Dermatol 1984; 111:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/34\">",
"      Ferreira M, Davies SL, Butler M, et al. Endomysial antibody: is it the best screening test for coeliac disease? Gut 1992; 33:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/35\">",
"      Grodzinsky E, Hed J, Skogh T. IgA antiendomysium antibodies have a high positive predictive value for celiac disease in asymptomatic patients. Allergy 1994; 49:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/36\">",
"      Kapuscinska A, Zalewski T, Chorzelski TP, et al. Disease specificity and dynamics of changes in IgA class anti-endomysial antibodies in celiac disease. J Pediatr Gastroenterol Nutr 1987; 6:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/37\">",
"      Kumar V, Lerner A, Valeski JE, et al. Endomysial antibodies in the diagnosis of celiac disease and the effect of gluten on antibody titers. Immunol Invest 1989; 18:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/38\">",
"      Unsworth DJ, Brown DL. Serological screening suggests that adult coeliac disease is underdiagnosed in the UK and increases the incidence by up to 12%. Gut 1994; 35:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/39\">",
"      Ladinser B, Rossipal E, Pittschieler K. Endomysium antibodies in coeliac disease: an improved method. Gut 1994; 35:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/40\">",
"      Volta U, Molinaro N, de Franceschi L, et al. IgA anti-endomysial antibodies on human umbilical cord tissue for celiac disease screening. Save both money and monkeys. Dig Dis Sci 1995; 40:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/41\">",
"      K&aacute;rp&aacute;ti S, Meurer M, Stolz W, et al. Ultrastructural binding sites of endomysium antibodies from sera of patients with dermatitis herpetiformis and coeliac disease. Gut 1992; 33:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/42\">",
"      Valeski JE, Kumar V, Beutner EH, et al. Immunology of celiac disease: tissue and species specificity of endomysial and reticulin antibodies. Int Arch Allergy Appl Immunol 1990; 93:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/43\">",
"      Dieterich W, Ehnis T, Bauer M, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997; 3:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/44\">",
"      Dieterich W, Laag E, Sch&ouml;pper H, et al. Autoantibodies to tissue transglutaminase as predictors of celiac disease. Gastroenterology 1998; 115:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/45\">",
"      Sulkanen S, Halttunen T, Laurila K, et al. Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease. Gastroenterology 1998; 115:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/46\">",
"      Troncone R, Maurano F, Rossi M, et al. IgA antibodies to tissue transglutaminase: An effective diagnostic test for celiac disease. J Pediatr 1999; 134:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/47\">",
"      Hopper AD, Cross SS, Hurlstone DP, et al. Pre-endoscopy serological testing for coeliac disease: evaluation of a clinical decision tool. BMJ 2007; 334:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/48\">",
"      Hopper AD, Hadjivassiliou M, Hurlstone DP, et al. What is the role of serologic testing in celiac disease? A prospective, biopsy-confirmed study with economic analysis. Clin Gastroenterol Hepatol 2008; 6:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/49\">",
"      Tonutti E, Visentini D, Bizzaro N, et al. The role of antitissue transglutaminase assay for the diagnosis and monitoring of coeliac disease: a French-Italian multicentre study. J Clin Pathol 2003; 56:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/50\">",
"      B&uuml;rgin-Wolff A, Hernandez R, Just M, Signer E. Immunofluorescent antibodies against gliadin: a screening test for coeliac disease. Helv Paediatr Acta 1976; 31:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/51\">",
"      Grodzinsky E, Franzen L, Hed J, Str&ouml;m M. High prevalence of celiac disease in healthy adults revealed by antigliadin antibodies. Ann Allergy 1992; 69:66.",
"     </a>",
"    </li>",
"    <li>",
"     Kelly CP. Coeliac disease: Non-invasive tests to screen for gluten sensitive enteropathy and to monitor response to dietary therapy, Dublin University, Trinity College, Dublin 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/53\">",
"      Kelly CP, Feighery CF, Gallagher RB, et al. Mucosal and systemic IgA anti-gliadin antibody in celiac disease. Contrasting patterns of response in serum, saliva, and intestinal secretions. Dig Dis Sci 1991; 36:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/54\">",
"      Kelly CP, Feighery CF, Gallagher RB, Weir DG. Diagnosis and treatment of gluten-sensitive enteropathy. Adv Intern Med 1990; 35:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/55\">",
"      Kilander AF, Nilsson LA, Gillberg R. Serum antibodies to gliadin in coeliac disease after gluten withdrawal. Scand J Gastroenterol 1987; 22:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/56\">",
"      Kilander AF, Dotevall G, F&auml;llstr&ouml;m SP, et al. Evaluation of gliadin antibodies for detection of coeliac disease. Scand J Gastroenterol 1983; 18:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/57\">",
"      O'Farrelly C, Kelly J, Hekkens W, et al. Alpha gliadin antibody levels: a serological test for coeliac disease. Br Med J (Clin Res Ed) 1983; 286:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/58\">",
"      Savilahti E, Viander M, Perkki&ouml; M, et al. IgA antigliadin antibodies: a marker of mucosal damage in childhood coeliac disease. Lancet 1983; 1:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/59\">",
"      Signer E, B&uuml;rgin-Wolff A, Berger R, et al. Antibodies to gliadin as a screening test for coeliac disease. A prospective study. Helv Paediatr Acta 1979; 34:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/60\">",
"      Corrao G, Corazza GR, Andreani ML, et al. Serological screening of coeliac disease: choosing the optimal procedure according to various prevalence values. Gut 1994; 35:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/61\">",
"      Abrams JA, Brar P, Diamond B, et al. Utility in clinical practice of immunoglobulin a anti-tissue transglutaminase antibody for the diagnosis of celiac disease. Clin Gastroenterol Hepatol 2006; 4:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/62\">",
"      Swallow K, Wild G, Sargur R, et al. Quality not quantity for transglutaminase antibody 2: the performance of an endomysial and tissue transglutaminase test in screening coeliac disease remains stable over time. Clin Exp Immunol 2013; 171:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/63\">",
"      Rostami K, Kerckhaert J, Tiemessen R, et al. Sensitivity of antiendomysium and antigliadin antibodies in untreated celiac disease: disappointing in clinical practice. Am J Gastroenterol 1999; 94:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/64\">",
"      Uibo O, Uibo R, Kleimola V, et al. Serum IgA anti-gliadin antibodies in an adult population sample. High prevalence without celiac disease. Dig Dis Sci 1993; 38:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/65\">",
"      Hvatum M, Scott H, Brandtzaeg P. Serum IgG subclass antibodies to a variety of food antigens in patients with coeliac disease. Gut 1992; 33:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/66\">",
"      Beutner EH, Kumar V, Chorzelski TP, Szaflarska-Czerwionka M. IgG endomysial antibodies in IgA-deficient patient with coeliac disease. Lancet 1989; 1:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/67\">",
"      Collin P, M&auml;ki M, Keyril&auml;inen O, et al. Selective IgA deficiency and coeliac disease. Scand J Gastroenterol 1992; 27:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/68\">",
"      Sinclair D, Saas M, Turk A, et al. Do we need to measure total serum IgA to exclude IgA deficiency in coeliac disease? J Clin Pathol 2006; 59:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/69\">",
"      Grodzinsky E, Hed J, Lied&eacute;n G, et al. Presence of IgA and IgG antigliadin antibodies in healthy adults as measured by micro-ELISA. Effect of various cutoff levels on specificity and sensitivity when diagnosing coeliac disease. Int Arch Allergy Appl Immunol 1990; 92:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/70\">",
"      Rubio-Tapia A, Kyle RA, Kaplan EL, et al. Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology 2009; 137:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/71\">",
"      Shanahan F, Weinstein WM. Extending the scope in celiac disease. N Engl J Med 1988; 319:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/72\">",
"      Kurien M, Evans KE, Aziz I, et al. Capsule endoscopy in adult celiac disease: a potential role in equivocal cases of celiac disease? Gastrointest Endosc 2013; 77:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/73\">",
"      Kaukinen K, Partanen J, M&auml;ki M, Collin P. HLA-DQ typing in the diagnosis of celiac disease. Am J Gastroenterol 2002; 97:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14377/abstract/74\">",
"      Ravelli A, Bolognini S, Gambarotti M, Villanacci V. Variability of histologic lesions in relation to biopsy site in gluten-sensitive enteropathy. Am J Gastroenterol 2005; 100:177.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4771 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.80.101-FFB583D007-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_2_14377=[""].join("\n");
var outline_f14_2_14377=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WHO SHOULD BE TESTED",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Serologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Testing on a gluten-free diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Small bowel biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Suggestive clinical features but negative serologic tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Positive serologic tests but negative small bowel biopsies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SERUM ANTIBODY ASSAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      IgA endomysial assay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Anti-tissue transglutaminase antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Antigliadin antibody assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Assay sensitivity and specificity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Role of antibodies in disease pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CLINICAL APPLICATION OF SEROLOGIC TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Individuals with a low risk for celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Individuals with a moderate or high risk for celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Monitoring adherence and response to gluten-free diet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SCREENING IN ASYMPTOMATIC INDIVIDUALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OTHER NONINVASIVE TESTS FOR THE DIAGNOSIS OF CELIAC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4771\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4771|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/45/23250\" title=\"algorithm 1\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/35/23102\" title=\"algorithm 2\">",
"      Proposed modified gluten challenge algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/57/43934\" title=\"algorithm 3\">",
"      Dx small intestinal villus atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4771|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/1/11281\" title=\"picture 1\">",
"      Celiac disease Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4771|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/1/16411\" title=\"table 1\">",
"      Differential diagnosis of small intestinal villous atrophy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2042?source=related_link\">",
"      Food allergens: Overview of clinical features and cross-reactivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4248?source=related_link\">",
"      Magnification endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=related_link\">",
"      Management of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/6/13410?source=related_link\">",
"      Patient information: Celiac disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/31/36339?source=related_link\">",
"      Patient information: Celiac disease in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/14/11492?source=related_link\">",
"      Patient information: Celiac disease in children (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_2_14378="Echocardiographic evaluation of the tricuspid valve";
var content_f14_2_14378=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Echocardiographic evaluation of the tricuspid valve",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/2/14378/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/2/14378/contributors\">",
"     Nelson B Schiller, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/2/14378/contributors\">",
"     Bryan Ristow, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/2/14378/contributors\">",
"     Xiushui Ren, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/2/14378/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/2/14378/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/2/14378/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/2/14378/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/2/14378/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/2/14378/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tricuspid valve disorders can be routinely identified and their severity estimated by echocardiography. From a technical standpoint, transthoracic echocardiography (TTE) of the tricuspid valve is slightly more challenging than it is for left-sided valves. The location of the tricuspid valve as the most rightward valve places it at or just beneath the sternal edge and requires the ultrasound beam to be angled sharply rightward while maintaining transducer contact with the chest wall. Image quality from the apical and subcostal windows is limited by far field beam attenuation and dispersion.",
"   </p>",
"   <p>",
"    Despite these impediments, the tricuspid valve can be adequately evaluated in most TTE examinations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ECHOCARDIOGRAPHY OF THE NORMAL TRICUSPID VALVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anatomically, the tricuspid valve consists of anterior, septal and posterior leaflets. The anterior leaflet is the most anatomically constant echocardiographic feature, with the septal and posterior leaflets being variable in size and position.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Transthoracic echocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;On two dimensional (2-D) TTE, the tricuspid valve is routinely recorded from the long (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56587 \" href=\"UTD.htm?10/48/11008\">",
"     image 1",
"    </a>",
"    ) and short axis parasternal, apical four chamber, and subcostal views. The normal tricuspid valve thickness is &lt;3 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Identification of individual tricuspid leaflets in the 2-D views has been controversial. Data from pathologic examination, rotational 2-D tomograms, and 2-D reconstructions from three-dimensional (3-D) images have facilitated correct leaflet identification in 2-D views [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the 2-D parasternal long axis (right ventricular inflow) view, the septal and anterior leaflets are generally visualized [",
"      <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/2,4-6\">",
"       2,4-6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the parasternal short axis view at the level of the aortic valve, the posterior leaflet is imaged along the right ventricular (RV) free wall and either the septal or anterior leaflet is imaged adjacent to the aortic root [",
"      <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/2,4,5\">",
"       2,4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the apical four chamber view, the anterior and septal leaflets are visualized [",
"      <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/2-5,7\">",
"       2-5,7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three dimensional imaging of the tricuspid valve enables en face visualization of the three leaflets [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/4,8\">",
"     4,8",
"    </a>",
"    ] in addition to facilitating leaflet identification in 2-D views [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tricuspid valve annulus is slightly apically displaced compared with the mitral valve annulus; the gap resulting from this displacement is occupied by the membranous septum that separates the left ventricle from the right atrium. Attention to this feature is useful in identifying the tricuspid valve in many congenital conditions (such as Ebstein's anomaly) and in understanding the anatomic substrate for congenital or acquired left ventricular to right atrial shunts (via a Gerbode defect). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=see_link\">",
"     \"Ebstein's anomaly of the tricuspid valve\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8506?source=see_link&amp;anchor=H30#H30\">",
"     \"Pathophysiology and clinical features of isolated ventricular septal defects in infants and children\", section on 'LV to RA shunting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Transesophageal echocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging the tricuspid valve with transesophageal echocardiography (TEE) is more difficult to accomplish than imaging the mitral and aortic valves as the tricuspid valve is generally further from the transducer than the left sided valves. The higher frequency waves used in TEE do not penetrate deeply into the far field.",
"   </p>",
"   <p>",
"    The tricuspid valve is best visualized in multiple TEE planes: the mid-esophageal four-chamber view at 0&ordm;, rotation at the mid-esophageal level to 30&ordm;, 60&ordm;, and 90&ordm; and from the transgastric view.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the four-chamber view, the septal and anterior leaflets are usually seen, and retroflexing the probe can bring the posterior leaflet into view.",
"     </li>",
"     <li>",
"      Tricuspid regurgitation jet velocity is best measured in a view in which the ultrasound beam and the regurgitant jet are most parallel, often between 30&ordm; and 90&ordm; in the mid-esophageal view.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Measurement of tricuspid regurgitation jet velocity to estimate pressure gradients is discussed below. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Peak velocity of the jet'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the transgastric position, the tricuspid valve is brought into view by turning the probe clockwise from the mitral valve short axis view (0&ordm;) or left ventricular long axis view (90&ordm;).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Depending upon an individual patient's anatomy, slight modification of the above views may be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TRICUSPID STENOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tricuspid stenosis is rare and is almost always acquired as a result of rheumatic fever. Rheumatic tricuspid stenosis is usually associated with mitral valve stenosis as well as tricuspid regurgitation. Other, less common causes of tricuspid stenosis include congenital tricuspid atresia, tricuspid valve tumors, endomyocardial fibrosis and carcinoid heart disease, which typically manifests predominantly with tricuspid regurgitation. Rare causes, such as pacemaker-related endocarditis, have also been reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5558?source=see_link\">",
"     \"Tricuspid stenosis: Clinical features, diagnosis, and percutaneous tricuspid balloon valvotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Two-dimensional echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two-dimensional TTE or TEE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/9\">",
"     9",
"    </a>",
"    ] enables identification of the specific features of tricuspid stenosis. Similar to mitral stenosis, the hallmark for the diagnosis is doming of the tricuspid valve seen in the parasternal long-axis view or in the apical four-chamber view. Other 2-D echocardiographic findings include thickening and calcification of the leaflets and restrictive leaflet motion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Doppler echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler echocardiography is useful for diagnosing tricuspid stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/10\">",
"     10",
"    </a>",
"    ]. Recordings for tricuspid stenosis are similar to those seen for mitral stenosis: there is turbulent diastolic inflow, higher than normal maximal flow during diastole, and an increased pressure half-time. The mean tricuspid diastolic gradient can be estimated from the tricuspid inflow time velocity integral by applying the modified Bernoulli equation.",
"   </p>",
"   <p>",
"    Estimating tricuspid valve area using echocardiography is not as well-established as estimating mitral valve area. Methods for calculating mitral valve area, such as pressure half-time, the continuity equation, and proximal isovelocity surface area, can be applied to the tricuspid valve. Tricuspid valve area in cm",
"    <sup>",
"     2",
"    </sup>",
"    may be estimated as 190 divided by the pressure half-time [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/11\">",
"     11",
"    </a>",
"    ]. The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines and 2008 focused update classify a tricuspid valve with valve area less than 1 cm",
"    <sup>",
"     2",
"    </sup>",
"    as being severely stenotic [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TRICUSPID REGURGITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1908, Sir James Mackenzie, noted that \"although actual disease of the valve is rare, incompetence of the tricuspid orifice is extremely common, so common indeed, that I am inclined to look upon the valves as being barely able to close the orifice perfectly.\" This statement was based upon observations made by means of meticulous kymographic recordings of precordial, cervical and subcostal pulsations.",
"   </p>",
"   <p>",
"    The universal availability of Doppler methods has confirmed this impression by demonstrating that about 70 percent of normal individuals have evidence of trace or functional tricuspid regurgitation and more than 90 percent with established heart disease have evidence of tricuspid regurgitation. In the normal individual, the finding of trivial and mild (1+) tricuspid regurgitation is rarely of clinical importance beyond providing a means of obtaining an accurate determination of pulmonary artery systolic pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Echocardiography provides a means to estimate the severity of tricuspid regurgitation, measure the velocity of tricuspid regurgitation (to estimate the systolic right ventricular to right atrial gradient), and identify the mechanism responsible for tricuspid regurgitation. As explained below, the magnitude of the tricuspid regurgitation gradient does not necessarily correlate with tricuspid regurgitation severity. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Peak velocity of the jet'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Two dimensional echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;On 2-D TTE or TEE, the presence and degree of tricuspid regurgitation can be evaluated by inspection of RV size and function, right atrial size and function, the tricuspid valve, and the vena cavae (",
"    <a class=\"graphic graphic_movie graphicRef53665 \" href=\"UTD.htm?1/18/1315\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82526 \" href=\"UTD.htm?22/36/23106\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62672 \" href=\"UTD.htm?33/26/34210\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Right ventricular size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamically significant chronic tricuspid regurgitation is generally associated with dilation of the RV. Methods for identifying RV enlargement are largely qualitative and the use of this finding as a guide to severity is also qualitative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27766?source=see_link\">",
"     \"Echocardiographic evaluation of the right ventricle\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Right ventricular function",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the presence of significant tricuspid regurgitation, the RV may become hyperdynamic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=see_link\">",
"     \"Hemodynamics of valvular disorders as measured by cardiac catheterization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is useful to examine the descent of the RV base toward the apex as a guide to RV systolic function. The excursion of RV base frequently becomes accentuated when significant tricuspid regurgitation is present [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. However, the RV may fail and become hypokinetic in the setting of severe tricuspid regurgitation and chronic overload; in this setting, RV systolic function may not adequately reflect tricuspid regurgitation severity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Interventricular septum",
"    </span>",
"    &nbsp;&mdash;&nbsp;When severe tricuspid regurgitation is present, RV volume overload causes diastolic interventricular septal flattening. The left ventricle becomes D-shaped, as increased preload in the RV displaces the septum toward the left. Septal flattening is best appreciated in the short-axis view at the level of the basal or mid-left ventricle. However, this sign is not specific for severe tricuspid regurgitation. If severe tricuspid regurgitation coexists with pulmonary hypertension, septal flattening can occur in both systole and diastole.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Right atrial size",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the normal state, the right and left atria appear to be nearly equal in size and shape. With isolated tricuspid regurgitation, the right atrium appears enlarged and spherical when compared to the left. The degree of atrial enlargement depends upon many factors, including the duration and severity of tricuspid regurgitation, intrinsic disease of atrial muscle, and, if present, the duration of chronic atrial fibrillation. A normal-sized right atrium coexisting with severe tricuspid regurgitation suggests that the valve lesion is of recent onset [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Right atrial volume changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The echocardiographic appearance of changes in right atrial size during the cardiac cycle are usually subtle. In the presence of significant tricuspid regurgitation, the volume changes in the right atrium during the cardiac cycle are exaggerated and more visually obvious. If the RV systolic function is normal, the descent of the RV base will also have exaggerated motion, both in absolute displacement and relative to motion of the left ventricular base. The inequality of motion gives a rocking appearance to the annular plane and to the right atrium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Interatrial septum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normally, the flexible interatrial septum moves bidirectionally or slightly left to right during atrial filling, reflecting the slightly higher filling pressure of the left heart [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/17\">",
"     17",
"    </a>",
"    ]. In the presence of severe tricuspid regurgitation, the normal curvature is reversed with the interatrial septum bulging from right to left when the jet impinges on the septum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RV filling pressure is elevated relative to the left.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Tricuspid valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tricuspid valve usually has an unremarkable appearance, since the most common cause of a pathologic tricuspid regurgitation is functional. With functional tricuspid regurgitation, the leaflets are intrinsically normal but dilation of the tricuspid annulus and, in severe cases, failure of leaflet coaptation may be qualitatively appreciated. Leaflet coaptation may be apically displaced, a finding that has been advocated as a method for recognizing impaired coaptation and identifying significant tricuspid regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/18\">",
"     18",
"    </a>",
"    ]. However, it is not clear if this finding is a result of RV dysfunction or an independent measure of the severity of tricuspid regurgitation. Tricuspid valve appearance with specific lesions is discussed below. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Lesions causing tricuspid regurgitation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Inferior vena cava",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inferior vena cava and hepatic veins can be imaged in the subcostal view. The vena cava expands in systole in response to tricuspid regurgitation and retrograde V waves. With more advanced degrees of tricuspid regurgitation, the systolic expansion of the inferior vena cava is visually apparent (",
"    <a class=\"graphic graphic_movie graphicRef50740 \" href=\"UTD.htm?9/28/9679\">",
"     movie 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef60413 \" href=\"UTD.htm?10/34/10799\">",
"     movie 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68087 \" href=\"UTD.htm?1/53/1876\">",
"     image 4",
"    </a>",
"    ). Inferior vena cava size and its respiratory variation can be used to estimate right atrial pressure.",
"   </p>",
"   <p>",
"    Pulse wave Doppler examination of hepatic veins is discussed below. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Pulse wave Doppler'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Color-flow Doppler echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The color-flow Doppler echocardiogram is the best way to establish the presence of tricuspid regurgitation and help grade its severity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/10\">",
"     10",
"    </a>",
"    ]. As for mitral regurgitation, several methods have been used to establish the severity of tricuspid regurgitation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66114 \" href=\"UTD.htm?2/62/3040\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef80498 \" href=\"UTD.htm?2/25/2448\">",
"     movie 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef68814 \" href=\"UTD.htm?9/1/9232\">",
"     movie 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef70050 \" href=\"UTD.htm?24/55/25459\">",
"     movie 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef56009 \" href=\"UTD.htm?7/41/7829\">",
"     movie 7",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Color-flow jet size",
"    </span>",
"    &nbsp;&mdash;&nbsp;The size of the color flow jet in the right atrium is proportional to the severity of tricuspid regurgitation. The tricuspid regurgitation jet area correlates with angiographic severity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/19-21\">",
"     19-21",
"    </a>",
"    ] as well as clinical evidence of tricuspid regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/22\">",
"     22",
"    </a>",
"    ]. Color jets associated with severe tricuspid regurgitation are easy to detect at low gain settings and appear to fill the right atrium. Very small jets are diagnostic of functional, minimal, trace, trivial or mild tricuspid regurgitation.",
"   </p>",
"   <p>",
"    However, experience suggests that there is only a rough relationship between the size, penetration and intensity of the jet and tricuspid regurgitation severity. There is significant overlap in jet area among grades of tricuspid regurgitation, particularly mild and moderate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Jet size is also influenced by entrainment, which is described in the next section.",
"   </p>",
"   <p>",
"    The 2003 ASE recommendations include tricuspid regurgitation classification by jet size with the above caveats [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/10\">",
"     10",
"    </a>",
"    ]. Jet area is not recommended as the sole parameter to grade tricuspid regurgitation severity. For central jets imaged using a Nyquist limit of 50 to 60",
"    <span class=\"nowrap\">",
"     cm/sec,",
"    </span>",
"    a jet area of &lt;5 cm2 suggests mild, 5 to 10 cm2 suggests moderate and &gt;10 cm2 suggests severe tricuspid regurgitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Entrainment of the jet",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the jet enters the right atrium, it becomes eccentric and hugs the atrial wall; this is called entrainment or the Coanda effect. The jet area of an eccentric jet impinging upon the wall of the receiving chamber will appear smaller than a centrally directed jet with the same regurgitant volume. Once entrained on the wall, the jet may completely circle the chamber. In mitral regurgitation, a \"wall-hugging jet\" entrained along an atrial wall is usually indicative of high grade regurgitation. While this phenomenon has not been formally studied in TR, experience suggests that this sign is frequently present with lesser degrees of tricuspid regurgitation and therefore cannot be considered a reliable sign of severity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=see_link\">",
"     \"Echocardiographic evaluation of the mitral valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Proximal flow acceleration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal flow acceleration describes the phenomenon of increasing blood velocity as regurgitant blood approaches the regurgitant orifice from the ventricular side of the valve. By color flow imaging, this phenomenon may be visualized as a series of concentric roughly hemispheric isovelocity shells of decreasing surface area and increasing surface velocity.",
"   </p>",
"   <p>",
"    The relatively low sampling rate of color flow imaging limits the peak measurable blood velocity. When flow velocity exceeds the aliasing velocity (Nyquist limit), color reversal occurs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15365?source=see_link&amp;anchor=H7#H7\">",
"     \"Principles of Doppler echocardiography\", section on 'Color flow imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Color flow imaging displays the convergence signal known as proximal isovelocity surface area (PISA) as a hemispheric shell with surface velocity equal to the chosen aliasing velocity (Va) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/16\">",
"     16",
"    </a>",
"    ]. At a given aliasing velocity, the radius (r) of PISA increases with increasing regurgitant volume. The effective regurgitant orifice area (EROA) can be calculated by dividing the flow rate through the regurgitant orifice (which is estimated as the product of the surface area of the hemisphere (2&pi;r2) and Va) by the peak velocity of the regurgitant jet (PkVreg):",
"   </p>",
"   <p>",
"    EROA = (2&pi;r2 *",
"    <span class=\"nowrap\">",
"     Va)/PkVreg",
"    </span>",
"   </p>",
"   <p>",
"    PISA has been extensively studied as a moderately accurate means of quantifying severity of mitral regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/23\">",
"     23",
"    </a>",
"    ]. Limitations of PISA include reduced accuracy for eccentric jets and, compared to central jets, difficulty in identifying the regurgitant orifice and inaccurate estimation of the convergence shape [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/24\">",
"     24",
"    </a>",
"    ]. Application of PISA to tricuspid regurgitation is limited by greater difficulty in visualizing a measurable contour of flow convergence [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Validation of the PISA method for tricuspid regurgitation has been performed in only a few studies. These have indicated that PISA derived measurements correlate with angiographic grade of tricuspid regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/20\">",
"     20",
"    </a>",
"    ] and other echocardiographic measures of tricuspid regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/21,25\">",
"     21,25",
"    </a>",
"    ]. In a study of 95 patients with tricuspid regurgitation and 95 patients with mitral regurgitation, similar EROAs were associated with smaller regurgitant volumes for tricuspid regurgitation compared to mitral regurgitation but a similar prevalence of venous flow reversal [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/25\">",
"     25",
"    </a>",
"    ]. Based upon these findings, an EROA of &ge;40 mm2 was recommended as a criterion of severe regurgitation in both tricuspid regurgitation and mitral regurgitation.",
"   </p>",
"   <p>",
"    The 2003 ASE guideline recommendations include PISA radius as a parameter for grading tricuspid regurgitation severity, although the guidelines note that such quantification is rarely needed clinically given the availability of other methods, such as the width of the vena contracta [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/16\">",
"     16",
"    </a>",
"    ]. At a Nyquist limit of 28",
"    <span class=\"nowrap\">",
"     cm/sec,",
"    </span>",
"    a tricuspid regurgitation PISA radius of &le;0.5 cm is categorized as mild, a radius of 0.6 to 0.9 cm is moderate, and a radius of &gt;0.9 cm is severe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Width of the vena contracta",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vena contracta is the narrowest portion of the color flow regurgitant jet that occurs at or just downstream from the valve orifice. Vena contracta width correlates with other echocardiographic measures of tricuspid regurgitation severity and with clinical evidence of tricuspid regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/22,26\">",
"     22,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2003 ASE recommendations grade tricuspid regurgitation as severe if the vena contracta width is &gt;0.7 cm at a Nyquist limit of 50 to 60",
"    <span class=\"nowrap\">",
"     cm/sec",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/16\">",
"     16",
"    </a>",
"    ]. The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines with 2008 update grade tricuspid regurgitation as severe if vena contracta width is &gt;0.7 cm and there is systolic flow reversal in the hepatic veins [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Support for these recommendations comes from a study of 71 patients with tricuspid regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/26\">",
"     26",
"    </a>",
"    ]. In comparison to jet area and",
"    <span class=\"nowrap\">",
"     jet/right",
"    </span>",
"    atrial ratio, the vena contracta width correlated more closely with EROA. Vena contracta width also correlated with hepatic venous flow, regurgitant volume, and right atrial area. A vena contracta width &ge;0.65 cm identified severe tricuspid regurgitation with a sensitivity of 89 percent and specificity of 93 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Comparison of color Doppler methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both PISA and vena contracta methods may be more accurate than jet area [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/15\">",
"     15",
"    </a>",
"    ]. Visualization of the vena contracta is less technically demanding than use of PISA. Both jet area and PISA underestimate severe tricuspid regurgitation in 20 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All of these color Doppler methods are more accurate for grading severity of central compared to eccentric TR jets. It may be difficult to distinguish mild from moderate tricuspid regurgitation by either the jet area or vena contracta methods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Pulse wave Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early diastolic peak velocity (peak E) and velocity time integral of RV inflow is increased in proportion to tricuspid regurgitation severity. These findings are analogous to those seen with mitral regurgitation, although the threshold for abnormally increased peak E is lower for tricuspid regurgitation than for mitral regurgitation.",
"   </p>",
"   <p>",
"    In a study of 118 patients with varying degrees of tricuspid regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/28\">",
"     28",
"    </a>",
"    ], tricuspid peak E was compared to tricuspid regurgitation graded according to ASE recommended parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/16\">",
"     16",
"    </a>",
"    ]. Tricuspid peak E of &ge; 0.65",
"    <span class=\"nowrap\">",
"     m/sec",
"    </span>",
"    had a sensitivity of 73 percent and specificity of 88 percent for the detection of severe TR.",
"   </p>",
"   <p>",
"    Since peak E is augmented in the presence of regurgitation, an E-wave dominant (E&gt;A) mitral inflow pattern is observed in the presence of significant MR [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/29\">",
"     29",
"    </a>",
"    ]. The presence of an A-wave dominant mitral inflow pattern excludes the presence of severe mitral regurgitation. Although the predictive value of an A-wave dominant tricuspid inflow pattern for excluding tricuspid regurgitation has not been reported, clinical experience indicates that an A-wave dominant pattern eliminates significant tricuspid regurgitation.",
"   </p>",
"   <p>",
"    Although tricuspid regurgitant volume can theoretically be calculated by subtracting the flow across a non-regurgitant valve from antegrade tricuspid flow, this approach is generally not used, partially due to difficulty estimating tricuspid annular area [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Inferior vena caval flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the presence of tricuspid regurgitation, pulse wave and color Doppler imaging can demonstrate alterations in inferior vena caval and hepatic vein flow. Blood flow in these vessels is generally toward the heart during both phases of the cardiac cycle. During inspiration, the normally dominant systolic inflow signal is exaggerated. Under normal conditions, retrograde caval flow occurs only briefly after atrial contraction.",
"   </p>",
"   <p>",
"    The flow reversal during systole in the hepatic veins with tricuspid regurgitation is analogous to flow reversal in pulmonary venous flow with mitral regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/29\">",
"     29",
"    </a>",
"    ]. In the presence of significant tricuspid regurgitation, the normally dominant systolic component of flow may be blunted or reversed (",
"    <a class=\"graphic graphic_movie graphicRef60413 \" href=\"UTD.htm?10/34/10799\">",
"     movie 3",
"    </a>",
"    ) and, during inspiration, the abnormality becomes accentuated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted in the 2003 ASE recommendations, moderate tricuspid regurgitation is associated with blunting of the normally dominant systolic wave of venous return and severe tricuspid regurgitation is associated with systolic venous flow reversal [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/16\">",
"     16",
"    </a>",
"    ]. The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for valvular disease characterize severe tricuspid regurgitation by systolic flow reversal in hepatic veins and a vena contracta width &gt;0.7 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Continuous wave Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several features of the continuous wave Doppler spectral recording that are useful in tricuspid regurgitation, including the shape, density, and peak velocity of the jet (",
"    <a class=\"graphic graphic_figure graphicRef67929 \" href=\"UTD.htm?21/31/22000\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71534 \" href=\"UTD.htm?42/46/43759\">",
"     image 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Shape of the jet",
"    </span>",
"    &nbsp;&mdash;&nbsp;The shape of the tricuspid regurgitation jet as recorded by continuous wave Doppler is usually symmetrically parabolic, reflecting the relative equality of rates of flow acceleration and deceleration. In severe tricuspid regurgitation, the intrusion of a large regurgitant volume into the right atrium during systole exceeds the ability of atrial capacitance or compliance to maintain low pressure and a rapid rise in atrial late systolic pressure occurs. This rise or V-wave produces early equilibration of right atrial and RV pressures, creating an asymmetric early peaking triangular regurgitant wave form.",
"   </p>",
"   <p>",
"    The 2003 ASE recommendations include jet contour as a parameter to grade tricuspid regurgitation. Mild tricuspid regurgitation is associated with a parabolic shape, moderate tricuspid regurgitation is associated with a variable contour, and severe tricuspid regurgitation is associated with a triangular early peaking jet [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/16\">",
"     16",
"    </a>",
"    ]. In our experience, the V-wave cut-off sign produced by early deceleration of the tricuspid regurgitation jet is one of the most useful and reliable signs of severe TR [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Density of the jet",
"    </span>",
"    &nbsp;&mdash;&nbsp;With mild tricuspid regurgitation, it is difficult to obtain a complete Doppler wave form (envelope) without the use of contrast enhancement of the signal; with more severe degrees of tricuspid regurgitation, the jet is completely outlined and the signal is dense. As the degree of severity increases, the jet progressively darkens and approaches the density of the tricuspid inflow jet.",
"   </p>",
"   <p>",
"    The strength of the Doppler signal is proportional to the number of red blood cells serving as reflecting targets. As a result, the tricuspid inflow signal is proportional to the volume of systemic flow and the relative density of the regurgitant signal indicates the magnitude of the regurgitant fraction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/33\">",
"     33",
"    </a>",
"    ]. The 2003 ASE recommendations grade \"soft\" TR jets as mild and \"dense\" TR jets as moderate or severe [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Peak velocity of the jet",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peak tricuspid regurgitation gradient can be estimated by applying the modified Bernoulli equation",
"    <span class=\"nowrap\">",
"     (&Delta;P",
"    </span>",
"    = 4v2 where",
"    <span class=\"nowrap\">",
"     &Delta;P",
"    </span>",
"    is the difference between right atrial pressure [RAP] and RV systolic pressure [RVSP] in mmHg and v is the peak velocity of the tricuspid regurgitation jet in",
"    <span class=\"nowrap\">",
"     meters/sec).",
"    </span>",
"    Accurate measurement of peak velocity requires a low intercept angle between the regurgitant jet and the ultrasound beam. If the intercept angle is high, the velocity may be underestimated.",
"   </p>",
"   <p>",
"    Peak RVSP can be estimated by summing estimated RAP and the estimated peak tricuspid regurgitation gradient (RVSP = RAP +",
"    <span class=\"nowrap\">",
"     &Delta;P)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/34\">",
"     34",
"    </a>",
"    ]. The RVSP is equal to the pulmonary artery systolic pressure (PASP) minus any pulmonic valve systolic gradient. If pulmonic stenosis (or other cause of RV outflow obstruction) is absent, RVSP equals PASP. Reference hemodynamic values are displayed in the table (",
"    <a class=\"graphic graphic_table graphicRef70326 \" href=\"UTD.htm?42/43/43709\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The 2003",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommend use of echocardiography to evaluate suspected pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/10\">",
"     10",
"    </a>",
"    ]. They also recommend echocardiography to follow-up pulmonary artery pressures in patients with pulmonary hypertension to evaluate the response to treatment. The 2007 echocardiography appropriateness criteria list echocardiography as appropriate for evaluation of known or suspected pulmonary hypertension including estimation of pulmonary artery pressure and evaluation of RV function [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peak velocity of the continuous wave Doppler tricuspid regurgitation jet is determined by RV systolic pressure, not the severity of tricuspid regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/36\">",
"     36",
"    </a>",
"    ]. Since tricuspid regurgitation velocity is determined by",
"    <span class=\"nowrap\">",
"     &Delta;P,",
"    </span>",
"    tricuspid regurgitation velocity is not an indicator of regurgitant fraction or volume (ie, tricuspid regurgitation severity) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the presence of severe pulmonary hypertension is not an indicator of severe tricuspid regurgitation. In the presence of wide-open severe tricuspid regurgitation, the peak velocity of the tricuspid regurgitation jet is generally only mildly to moderately elevated, reflecting a mild to moderate systolic gradient between the right atrium and RV. In this setting, accurate estimation of right atrial pressure (which may be markedly elevated) as well as tricuspid systolic gradient is required to accurately estimate pulmonary artery systolic pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Contrast echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of agitated saline or other ultrasound contrast agents can enhance the tricuspid regurgitation jet signal (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71534 \" href=\"UTD.htm?42/46/43759\">",
"     image 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/10\">",
"     10",
"    </a>",
"    ]. Since contrast administration requires intravenous access, its use for enhancing tricuspid regurgitation jets may be limited to situations in which access is readily available or contrast is being employed for another purpose. Contrast enhancement of weak tricuspid regurgitation velocity signal may permit more accurate determination of right heart hemodynamics.",
"   </p>",
"   <p>",
"    A right-sided contrast agent such as agitated saline may also enhance visualization of hepatic vein flow reversal. Following administration of contrast into an upper extremity vein, the inferior vena cava and hepatic veins are monitored for systolic appearance of contrast. Normally, only minimal contrast enters the hepatic veins but in the presence of significant tricuspid regurgitation, abnormal reflux can be detected by 2-D imaging, pulsed Doppler, color Doppler, or M-mode.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     LESIONS CAUSING TRICUSPID REGURGITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The echocardiogram in conjunction with other clinical data can help establish the etiology of tricuspid regurgitation.",
"   </p>",
"   <p>",
"    The most common cause of tricuspid regurgitation is functional, which occurs secondary to tricuspid annular dilatation (due to RV or right atrial enlargement). Causes of functional tricuspid regurgitation include disease states that can cause RV dilatation and failure, such as left heart failure, pulmonary hypertension, left-to-right shunt, and RV infarction. Atrial fibrillation is also recognized as a cause of severe tricuspid regurgitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/9/149?source=see_link&amp;anchor=H3#H3\">",
"     \"Etiology, clinical features, and evaluation of tricuspid regurgitation\", section on 'Functional TR'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary disorders of the tricuspid valve causing regurgitation are much less common than functional tricuspid regurgitation. Causes of primary tricuspid regurgitation include rheumatic heart disease, tricuspid endocarditis, tricuspid prolapse, Ebstein's anomaly, and carcinoid heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/9/149?source=see_link&amp;anchor=H4#H4\">",
"     \"Etiology, clinical features, and evaluation of tricuspid regurgitation\", section on 'Valvular abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The etiology of tricuspid regurgitation may be evident only by TEE. Possible settings in which this might occur include vegetations with leaflet destruction, a flail tricuspid leaflet due to traumatic chordal rupture (occurring, for example, as a complication of diagnostic or follow-up myocardial transcatheter biopsy ), periprosthetic regurgitation, leaflet fixation due to a RV pacing lead, or inclusion of the septal leaflet in the formation of a ventricular septal aneurysm spontaneously closing a ventricular septal defect [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unusual tricuspid regurgitant jet direction is also encountered. As an example, these jets can contribute to the severity of right-to-left shunting in an atrial septal defect by direct streaming through the defect [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Functional tricuspid regurgitation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Left heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of tricuspid regurgitation is right heart failure secondary to left heart failure. In this situation, left ventricular dysfunction of any cause raises left atrial pressure and pulmonary artery pressure, and induces RV and right atrial dilatation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The severity of tricuspid regurgitation parallels the severity of right chamber enlargement. As the annulus dilates, the leaflets, fixed in length, overlap progressively less at their tips. With time, TR causes further chamber dilation and less leaflet coaptation. In this vicious cycle, tricuspid regurgitation begets more tricuspid regurgitation. The leaflets appear normal in thickness, annular attachment, and excursion, but the dwindling coaptation surface migrates apically.",
"   </p>",
"   <p>",
"    RV function may be depressed and this reduced function is recognized by diminished systolic descent of the anterior RV base (anterior tricuspid annulus). Effective treatment of left ventricular failure often results in a decrease or disappearance of tricuspid regurgitation, thereby confirming the diagnosis of functional TR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3890881\">",
"    <span class=\"h3\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic atrial fibrillation is associated with progressive left atrial and right atrial enlargement. In some, the tricuspid valve annulus dilates with the atrium and begets atrioventricular valve regurgitation. Regurgitation engenders further dilation of the valve rings and steady worsening of mitral and tricuspid regurgitation. In the background, worsening left ventricular diastolic function also may contribute to progressive regurgitation. Eventually, severe right heart failure may complicate this picture [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of rhythm versus rate control in managing atrial fibrillation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Pulmonary arterial hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tricuspid regurgitation commonly complicates pre-capillary pulmonary hypertension, regardless of cause (eg, primary, connective tissue disease, congenital disease). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When tricuspid regurgitation is present, it contributes to RV and right atrial dilation and right-sided heart failure. As in the presence of pulmonary hypertension due to left heart failure, the leaflets are usually anatomically normal in their echocardiographic appearance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Rheumatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatic disease, where prevalent, is a common cause of tricuspid regurgitation. In patients with rheumatic heart disease, significant tricuspid regurgitation almost never exists as an isolated lesion and generally accompanies rheumatic mitral involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/42\">",
"     42",
"    </a>",
"    ]. The degree of anatomic change affecting the tricuspid valve is almost always less than that affecting the mitral valve. Among patients with rheumatic mitral disease, tricuspid regurgitation occurs with normal as well as deformed leaflets [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rheumatic features including diffuse leaflet thickening, restriction of opening motion by commissural fusion, calcification of the leaflets, and chordal shortening [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/43\">",
"     43",
"    </a>",
"    ]. Restriction of leaflet mobility produces characteristic leaflets motion with failure to move apart and \"doming\" as a unit into the right ventricle during diastole.",
"   </p>",
"   <p>",
"    Rheumatic tricuspid regurgitation is frequently accompanied by tricuspid stenosis. Because the tricuspid valve annulus is large, tricuspid stenosis without regurgitation is considerably less common. In a study of 788 consecutive patients aged 9 to 64 with rheumatic heart disease in India, 9 percent had echocardiographic evidence of tricuspid valve involvement and all had mitral valve stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/42\">",
"     42",
"    </a>",
"    ]. Of these patients, 50 percent had tricuspid regurgitation, 7 percent had tricuspid stenosis, and 43 percent had combined tricuspid regurgitation and stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Tricuspid valve prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myxomatous disease of the mitral valve is often accompanied by tricuspid involvement but isolated tricuspid prolapse has been rarely reported [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/5\">",
"     5",
"    </a>",
"    ]. Among patients with mitral valve prolapse, the likelihood that the tricuspid valve will develop this form of degeneration increases with age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2648?source=see_link&amp;anchor=H4#H4\">",
"     \"Nonarrhythmic complications of mitral valve prolapse\", section on 'Prolapse of other valves'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prolapse is identified as superior systolic displacement of leaflets above the tricuspid valve annulus into the right atrium (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53562 \" href=\"UTD.htm?17/25/17823\">",
"     image 7",
"    </a>",
"    ). Additional echocardiographic features that may be present include varying degrees of diffuse leaflet thickening (ground glass, not calcific) and leaflet elongation. As with mitral valve prolapse, milder degrees of tricuspid valve prolapse show late systolic displacement and late systolic tricuspid regurgitation.",
"   </p>",
"   <p>",
"    Since the tricuspid valve annulus is nonplanar, the choice of imaging plane may impact the accuracy of diagnosis of prolapse. Analysis of tricuspid annular geometry by 3D echocardiography indicates that the tricuspid valve has a bimodal or saddle shape with an anterior high point between the anterior and septal leaflets and a posterior high point adjacent to the posterior leaflet [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 2D four chamber view, the mediolateral imaging plane cuts the tricuspid annulus along its inferior points. As a result, the leaflets may appear to prolapse superior to the annular rim in this view while they remain below the annular rim in the anteroposterior plane. These data suggest that the presence or absence of tricuspid valve prolapse is ideally evaluated in views aligned with the anteroposterior axis, such as the parasternal short axis view at the level of the aorta.",
"   </p>",
"   <p>",
"    Clinically important degrees of tricuspid regurgitation are uncommon in myxomatous disease but can occur, especially if there is spontaneous or iatrogenic chordal rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H43\">",
"     'Traumatic tricuspid valve disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Ischemic tricuspid regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial infarction of the RV free wall or interventricular septum may involve the wall supporting the papillary muscle with resulting tension on the chordae causing tricuspid regurgitation. The 2-D echocardiogram demonstrates incomplete and often asymmetric closure of the tricuspid leaflets with apical displacement of the coaptation point. This phenomenon is similar to that seen with left ventricular myocardial infarction with resulting loss of support of mitral papillary muscle, resulting in ischemic mitral regurgitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=see_link\">",
"     \"Ischemic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocarditis of the tricuspid valve most frequently occurs as a complication of illicit intravenous drug use. Right-sided endocarditis affects the tricuspid valve far more commonly than the pulmonic valve.",
"   </p>",
"   <p>",
"    Echocardiographic findings include mobile, often bulky vegetations that prolapse into the right atrium and distort valve continuity and may be accompanied by flail leaflet resulting from chordal destruction (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56693 \" href=\"UTD.htm?35/45/36566\">",
"     image 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef73652 \" href=\"UTD.htm?22/46/23279\">",
"     movie 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef70221 \" href=\"UTD.htm?0/29/466\">",
"     movie 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/47\">",
"     47",
"    </a>",
"    ]. When there is a flail leaflet, the degree of regurgitation is marked.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     TTE or TEE?",
"    </span>",
"    &nbsp;&mdash;&nbsp;When tricuspid endocarditis is suspected, TTE should be attempted first. If the clinical question is unanswered, then it is reasonable to proceed to TEE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The improved image quality that TEE usually offers over TTE is not as apparent in imaging tricuspid valve disease unless precordial images cannot be obtained (eg, soon after open heart surgery). Hemodynamic information derived from measurement of the tricuspid regurgitation jet is generally more readily obtained from the TTE approach.",
"   </p>",
"   <p>",
"    The sensitivity of TTE for detection of tricuspid valve vegetations was illustrated by a study of 48 intravenous drug users, who were young and perhaps more easily imaged [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/48\">",
"     48",
"    </a>",
"    ]. Vegetations were detected by TTE in all 22 patients with vegetations detected by TEE. The grading of tricuspid regurgitation was also identical with the two techniques, although TEE did give more detailed images of the vegetations.",
"   </p>",
"   <p>",
"    However, TTE will miss some tricuspid vegetations that are detectable by TEE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=see_link\">",
"     \"Role of echocardiography in infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TEE is essential for the diagnosis of endocarditis in some situations, such as infection of central venous catheters and pacemaker or implantable cardioverter-defibrillator leads. One example is that of immunocompromised patients receiving chemotherapy or hyperalimentation who develop vegetations on chronically placed, central venous catheters. TTE is often nondiagnostic in this setting. This was illustrated in a review of 19 patients in which TTE had a sensitivity of only 26 percent; in nine of these patients, TEE led to a major change in management, such as surgery, line removal, or antibiotic or anticoagulant therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Carcinoid tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoid tumors that have metastasized to the liver and produce large amounts of 5-hydroxyindoleacetic acid (HIAA) are associated with tricuspid regurgitation. The valve leaflets have a unique appearance in carcinoid heart disease, being shortened, thickened, and rigid with little change in position from systole to diastole [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/51\">",
"     51",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82526 \" href=\"UTD.htm?22/36/23106\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef56009 \" href=\"UTD.htm?7/41/7829\">",
"     movie 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef68261 \" href=\"UTD.htm?18/59/19381\">",
"     movie 10",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With advanced deformity, the leaflets appear to neither open nor close. Although small diastolic gradients occur in carcinoid, the predominant lesion is almost always severe regurgitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Ebstein's anomaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ebstein's anomaly is a congenital malformation characterized by exaggerated apical displacement of the functional tricuspid valve annulus relative to the mitral annulus. Echocardiography establishes the diagnosis and demonstrates its salient features. The diagnosis and management of Ebstein's anomaly are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=see_link\">",
"     \"Ebstein's anomaly of the tricuspid valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In Ebstein's anomaly, the septal and posterior leaflets are adherent to underlying myocardium so that their hinge points are apically displaced. The septal leaflet hinge point is apically displaced by &ge;8",
"    <span class=\"nowrap\">",
"     mm/m2",
"    </span>",
"    body surface area compared to the position of the mitral valve annulus in the apical four chamber view [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Ebstein's anomaly affects the septal leaflet most and the anterior the least but, in the more severe cases, the entire apparatus may situated in or near the apex [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/54\">",
"     54",
"    </a>",
"    ]. There is usually tricuspid regurgitation and right atrial enlargement, both of which can be severe.",
"   </p>",
"   <p>",
"    A unique feature of the regurgitant jet is that the origin of the jet is at the most apically displaced point of the valve. The portion of the RV that serves as a receiving chamber for tricuspid regurgitation is said to be atrialized (",
"    <a class=\"graphic graphic_figure graphicRef61728 \" href=\"UTD.htm?19/41/20114\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74450 \" href=\"UTD.htm?16/5/16465\">",
"     image 9",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When Ebstein's anomaly is identified, an agitated saline contrast study may be indicated to determine whether a patent foramen ovale or atrial septal defect is present, since one of these is present in the majority of patients (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50434 \" href=\"UTD.htm?10/29/10705\">",
"     image 10",
"    </a>",
"    ). M-mode timing of tricuspid motion can demonstrate the delayed closure of the tricuspid valve felt to be the origin of the sail sound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Pacemaker leads and tricuspid regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;RV pacemaker or implantable cardioverter-defibrillator leads and pulmonary artery catheters can cause alteration in tricuspid valve apposition with resulting tricuspid regurgitation. Occasionally, a follow-up echocardiogram after pacemaker placement will show a greater degree of tricuspid regurgitation than was present prior to the procedure. Shadowing from a pacemaker lead may occasionally obscure tricuspid regurgitation so imaging from multiple planes is essential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Traumatic tricuspid valve disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traumatic injuries of the chordae tendineae of the tricuspid valve have been described. Probably the most common cause is unintentional trauma to the subvalvular apparatus by a bioptome during transcatheter right heart myocardial biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/46,55-57\">",
"     46,55-57",
"    </a>",
"    ]. Occasionally, blunt chest trauma results in a chordal rupture or annular tear [",
"    <a class=\"abstract\" href=\"UTD.htm?14/2/14378/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systolic fluttering of the leaflets, similar to what is observed with mitral chordal rupture, can be detected by M-mode. If the leaflet is flail, it may be displaced (along with the severed chord) into the right atrium during systole and appear as a prolapsing mass. The echocardiographic appearance of a severed chord with flail leaflet can be difficult to distinguish from a vegetation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15397371\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The tricuspid valve consists of anterior, septal and posterior leaflets. The anterior leaflet is the most anatomically constant echocardiographic feature, with the septal and posterior leaflets being variable in size and position. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Echocardiography of the normal tricuspid valve'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The tricuspid valve annulus is slightly apically displaced compared with the mitral valve annulus; the gap resulting from this displacement is occupied by the membranous septum that separates the left ventricle from the right atrium. Attention to this feature is useful in identifying the tricuspid valve in many congenital conditions (such as Ebstein's anomaly) and in understanding the anatomic substrate for congenital or acquired left ventricular to right atrial shunts (via a Gerbode defect). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Transthoracic echocardiogram'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tricuspid stenosis is rare and is almost always due to rheumatic disease, which is usually associated with mitral valve stenosis as well as tricuspid regurgitation. Other, less common causes of tricuspid stenosis include congenital tricuspid atresia, tricuspid valve tumors, endomyocardial fibrosis and carcinoid heart disease, which typically manifests predominantly with tricuspid regurgitation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Tricuspid stenosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      About 70 percent of normal individuals have evidence of trace or functional tricuspid regurgitation and more than 90 percent with established heart disease have evidence of tricuspid regurgitation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Tricuspid regurgitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The severity of tricuspid regurgitation can be evaluated by color Doppler using jet size, proximal isovelocity surface area, or vena contracta width. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Color-flow Doppler echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe tricuspid regurgitation is identified by systolic flow reversal in the hepatic veins and a vena contracta width &gt;0.7 cm. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Inferior vena caval flow'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Width of the vena contracta'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The peak tricuspid regurgitation gradient can be estimated by applying the modified Bernoulli equation",
"      <span class=\"nowrap\">",
"       (&Delta;P",
"      </span>",
"      = 4v2 where",
"      <span class=\"nowrap\">",
"       &Delta;P",
"      </span>",
"      is the difference between right atrial pressure [RAP] and right ventricular systolic pressure [RVSP] and v is the peak velocity of the tricuspid regurgitation jet). (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Peak velocity of the jet'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the presence of wide-open severe tricuspid regurgitation, the peak velocity of the tricuspid regurgitation jet is generally only mildly to moderately elevated, reflecting a mild to moderate systolic gradient between the right atrium and right ventricle. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Peak velocity of the jet'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Causes of tricuspid regurgitation include tricuspid annular dilatation (eg, functional tricuspid regurgitation from left heart failure or atrial fibrillation), rheumatic heart disease, tricuspid endocarditis, tricuspid prolapse, Ebstein&rsquo;s anomaly, carcinoid heart disease, pacemaker leads, and trauma. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Lesions causing tricuspid regurgitation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/1\">",
"      Crawford MH, Roldan CA. Quantitative assessment of valve thickness in normal subjects by transesophageal echocardiography. Am J Cardiol 2001; 87:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/2\">",
"      Tajik AJ, Seward JB, Hagler DJ, et al. Two-dimensional real-time ultrasonic imaging of the heart and great vessels. Technique, image orientation, structure identification, and validation. Mayo Clin Proc 1978; 53:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/3\">",
"      Brown AK, Anderson V. Two dimensional echocardiography and the tricuspid valve. Leaflet definition and prolapse. Br Heart J 1983; 49:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/4\">",
"      Anwar AM, Geleijnse ML, Soliman OI, et al. Assessment of normal tricuspid valve anatomy in adults by real-time three-dimensional echocardiography. Int J Cardiovasc Imaging 2007; 23:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/5\">",
"      Tei C, Shah PM, Cherian G, et al. Echocardiographic evaluation of normal and prolapsed tricuspid valve leaflets. Am J Cardiol 1983; 52:796.",
"     </a>",
"    </li>",
"    <li>",
"     Otto C. Textbook of clinical echocardiography, 3rd ed, Elsevier Saunders, 2004.",
"    </li>",
"    <li>",
"     Feigenbaum H. Feigenbaum's Echocardiography, 6th ed, Lippincott, Williams &amp; Wilkins, Philadelphia 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/8\">",
"      Pothineni KR, Duncan K, Yelamanchili P, et al. Live/real time three-dimensional transthoracic echocardiographic assessment of tricuspid valve pathology: incremental value over the two-dimensional technique. Echocardiography 2007; 24:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/9\">",
"      Zaroff JG, Picard MH. Transesophageal echocardiographic (TEE) evaluation of the mitral and tricuspid valves. Cardiol Clin 2000; 18:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/10\">",
"      Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003; 108:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/11\">",
"      P&eacute;rez JE, Ludbrook PA, Ahumada GG. Usefulness of Doppler echocardiography in detecting tricuspid valve stenosis. Am J Cardiol 1985; 55:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/12\">",
"      Fawzy ME, Mercer EN, Dunn B, et al. Doppler echocardiography in the evaluation of tricuspid stenosis. Eur Heart J 1989; 10:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/13\">",
"      Schiller NB. Pulmonary artery pressure estimation by Doppler and two-dimensional echocardiography. Cardiol Clin 1990; 8:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/14\">",
"      Isaaz K, Munoz del Romeral L, Lee E, Schiller NB. Quantitation of the motion of the cardiac base in normal subjects by Doppler echocardiography. J Am Soc Echocardiogr 1993; 6:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/15\">",
"      Simonson JS, Schiller NB. Descent of the base of the left ventricle: an echocardiographic index of left ventricular function. J Am Soc Echocardiogr 1989; 2:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/16\">",
"      Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003; 16:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/17\">",
"      Kusumoto FM, Muhiudeen IA, Kuecherer HF, et al. Response of the interatrial septum to transatrial pressure gradients and its potential for predicting pulmonary capillary wedge pressure: an intraoperative study using transesophageal echocardiography in patients during mechanical ventilation. J Am Coll Cardiol 1993; 21:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/18\">",
"      Sagie A, Schwammenthal E, Padial LR, et al. Determinants of functional tricuspid regurgitation in incomplete tricuspid valve closure: Doppler color flow study of 109 patients. J Am Coll Cardiol 1994; 24:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/19\">",
"      Tu&ntilde;on J, Cordoba M, Rey M, et al. Assessment of chronic tricuspid regurgitation by colour Doppler echocardiography: a comparison with angiography in the catheterization room. Eur Heart J 1994; 15:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/20\">",
"      Gonzalez-Vilchez F, Zarauza J, Vazquez de Prada JA, et al. Assessment of tricuspid regurgitation by Doppler color flow imaging: angiographic correlation. Int J Cardiol 1994; 44:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/21\">",
"      Grossmann G, Stein M, Kochs M, et al. Comparison of the proximal flow convergence method and the jet area method for the assessment of the severity of tricuspid regurgitation. Eur Heart J 1998; 19:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/22\">",
"      Shapira Y, Porter A, Wurzel M, et al. Evaluation of tricuspid regurgitation severity: echocardiographic and clinical correlation. J Am Soc Echocardiogr 1998; 11:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/23\">",
"      Utsunomiya T, Doshi R, Patel D, et al. Regurgitant volume estimation in patients with mitral regurgitation: initial studies using color Doppler \"proximal isovelocity surface area\" method. Echocardiography 1992; 9:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/24\">",
"      Simpson IA, Shiota T, Gharib M, Sahn DJ. Current status of flow convergence for clinical applications: is it a leaning tower of \"PISA\"? J Am Coll Cardiol 1996; 27:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/25\">",
"      Tribouilloy CM, Enriquez-Sarano M, Capps MA, et al. Contrasting effect of similar effective regurgitant orifice area in mitral and tricuspid regurgitation: a quantitative Doppler echocardiographic study. J Am Soc Echocardiogr 2002; 15:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/26\">",
"      Tribouilloy CM, Enriquez-Sarano M, Bailey KR, et al. Quantification of tricuspid regurgitation by measuring the width of the vena contracta with Doppler color flow imaging: a clinical study. J Am Coll Cardiol 2000; 36:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/27\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/28\">",
"      Danicek V, Sagie A, Vaturi M, et al. Relation of tricuspid inflow E-wave peak velocity to severity of tricuspid regurgitation. Am J Cardiol 2006; 98:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/29\">",
"      Thomas L, Foster E, Schiller NB. Peak mitral inflow velocity predicts mitral regurgitation severity. J Am Coll Cardiol 1998; 31:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/30\">",
"      Skjaerpe T, Hatle L. Diagnosis of tricuspid regurgitation. Sensitivity of Doppler ultrasound compared with contrast echocardiography. Eur Heart J 1985; 6:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/31\">",
"      Sakai K, Nakamura K, Satomi G, et al. Evaluation of tricuspid regurgitation by blood flow pattern in the hepatic vein using pulsed Doppler technique. Am Heart J 1984; 108:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/32\">",
"      Imanishi T, Nakatani S, Yamada S, et al. Validation of continuous wave Doppler-determined right ventricular peak positive and negative dP/dt: effect of right atrial pressure on measurement. J Am Coll Cardiol 1994; 23:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/33\">",
"      Enriquez-Sarano M, Kaneshige AM, Tajik AJ, et al. Amplitude-weighted mean velocity: clinical utilization for quantitation of mitral regurgitation. J Am Coll Cardiol 1993; 22:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/34\">",
"      Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984; 70:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/35\">",
"      Douglas PS, Khandheria B, Stainback RF, et al. ACCF/ASE/ACEP/ASNC/SCAI/SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American Society of Echocardiography, American College of Emergency Physicians, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society for Cardiovascular Magnetic Resonance endorsed by the American College of Chest Physicians and the Society of Critical Care Medicine. J Am Coll Cardiol 2007; 50:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/36\">",
"      Hinderliter AL, Willis PW 4th, Long WA, et al. Frequency and severity of tricuspid regurgitation determined by Doppler echocardiography in primary pulmonary hypertension. Am J Cardiol 2003; 91:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/37\">",
"      Waller BF, Moriarty AT, Eble JN, et al. Etiology of pure tricuspid regurgitation based on anular circumference and leaflet area: analysis of 45 necropsy patients with clinical and morphologic evidence of pure tricuspid regurgitation. J Am Coll Cardiol 1986; 7:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/38\">",
"      Winslow TM, Redberg RF, Foster E, Schiller NB. Transesophageal echocardiographic detection of abnormalities of the tricuspid valve in adults associated with spontaneous closure of perimembranous ventricular septal defect. Am J Cardiol 1992; 70:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/39\">",
"      Kai H, Koyanagi S, Hirooka Y, et al. Right-to-left shunt across atrial septal defect related to tricuspid regurgitation: assessment by transesophageal Doppler echocardiography. Am Heart J 1994; 127:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/40\">",
"      Hansing CE, Rowe GG. Tricuspid insufficiency. A study of hemodynamics and pathogenesis. Circulation 1972; 45:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/41\">",
"      Najib MQ, Vinales KL, Vittala SS, et al. Predictors for the development of severe tricuspid regurgitation with anatomically normal valve in patients with atrial fibrillation. Echocardiography 2012; 29:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/42\">",
"      Goswami KC, Rao MB, Dev V, Shrivastava S. Juvenile tricuspid stenosis and rheumatic tricuspid valve disease: an echocardiographic study. Int J Cardiol 1999; 72:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/43\">",
"      Hannoush H, Fawzy ME, Stefadouros M, et al. Regression of significant tricuspid regurgitation after mitral balloon valvotomy for severe mitral stenosis. Am Heart J 2004; 148:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/44\">",
"      Werner JA, Schiller NB, Prasquier R. Occurrence and significance of echocardiographically demonstrated tricuspid valve prolapse. Am Heart J 1978; 96:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/45\">",
"      Ton-Nu TT, Levine RA, Handschumacher MD, et al. Geometric determinants of functional tricuspid regurgitation: insights from 3-dimensional echocardiography. Circulation 2006; 114:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/46\">",
"      Lewen MK, Bryg RJ, Miller LW, et al. Tricuspid regurgitation by Doppler echocardiography after orthotopic cardiac transplantation. Am J Cardiol 1987; 59:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/47\">",
"      Chandraratna PA, Aronow WS. Spectrum of echocardiographic findings in tricuspid valve endocarditis. Br Heart J 1979; 42:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/48\">",
"      San Rom&aacute;n JA, Vilacosta I, Zamorano JL, et al. Transesophageal echocardiography in right-sided endocarditis. J Am Coll Cardiol 1993; 21:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/49\">",
"      Reynolds HR, Jagen MA, Tunick PA, Kronzon I. Sensitivity of transthoracic versus transesophageal echocardiography for the detection of native valve vegetations in the modern era. J Am Soc Echocardiogr 2003; 16:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/50\">",
"      Cohen GI, Klein AL, Chan KL, et al. Transesophageal echocardiographic diagnosis of right-sided cardiac masses in patients with central lines. Am J Cardiol 1992; 70:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/51\">",
"      Himelman RB, Schiller NB. Clinical and echocardiographic comparison of patients with the carcinoid syndrome with and without carcinoid heart disease. Am J Cardiol 1989; 63:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/52\">",
"      Edwards WD. Embryology and pathologic features of Ebstein's anomaly. Prog Pediatr Cardiol 1993;2:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/53\">",
"      Shiina A, Seward JB, Tajik AJ, et al. Two-dimensional echocardiographic--surgical correlation in Ebstein's anomaly: preoperative determination of patients requiring tricuspid valve plication vs replacement. Circulation 1983; 68:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/54\">",
"      Ports TA, Silverman NH, Schiller NB. Two-dimensional echocardiographic assessment of Ebstein's anomaly. Circulation 1978; 58:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/55\">",
"      Hausen B, Albes JM, Rohde R, et al. Tricuspid valve regurgitation attributable to endomyocardial biopsies and rejection in heart transplantation. Ann Thorac Surg 1995; 59:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/56\">",
"      Reddy SC, Rath GA, Ziady GM, et al. Tricuspid flail leaflets after orthotopic heart transplant: a new complication of endomyocardial biopsy. J Am Soc Echocardiogr 1993; 6:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/57\">",
"      Nguyen V, Cantarovich M, Cecere R, Giannetti N. Tricuspid regurgitation after cardiac transplantation: how many biopsies are too many? J Heart Lung Transplant 2005; 24:S227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/58\">",
"      Bonmassari R, Nicolosi GL, Disertori M. [Tricuspid insufficiency with rupture of the chordae tendineae caused by closed thoracic trauma: evaluation by transesophageal echocardiography. Description of a case]. G Ital Cardiol 1994; 24:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/2/14378/abstract/59\">",
"      Tatebe S, Uehara A, Shinonaga M, Kuraoka S. Posttraumatic tricuspid insufficiency successfully repaired by conventional technique. J Card Surg 2005; 20:356.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5292 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-F1BE05E961-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_2_14378=[""].join("\n");
var outline_f14_2_14378=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15397371\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ECHOCARDIOGRAPHY OF THE NORMAL TRICUSPID VALVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Transthoracic echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Transesophageal echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TRICUSPID STENOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Two-dimensional echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TRICUSPID REGURGITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Two dimensional echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Right ventricular size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Right ventricular function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Interventricular septum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Right atrial size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Right atrial volume changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Interatrial septum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Inferior vena cava",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Color-flow Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Color-flow jet size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Entrainment of the jet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Proximal flow acceleration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Width of the vena contracta",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Comparison of color Doppler methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Pulse wave Doppler",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Inferior vena caval flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Continuous wave Doppler",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Shape of the jet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Density of the jet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Peak velocity of the jet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Contrast echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      LESIONS CAUSING TRICUSPID REGURGITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Functional tricuspid regurgitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Left heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3890881\">",
"      - Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Pulmonary arterial hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Tricuspid valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Ischemic tricuspid regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - TTE or TEE?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Ebstein's anomaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Pacemaker leads and tricuspid regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Traumatic tricuspid valve disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15397371\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5292\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5292|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/48/11008\" title=\"diagnostic image 1\">",
"      2D TTE RV inflow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/36/23106\" title=\"diagnostic image 2\">",
"      Apical 4 chamber carcinoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/26/34210\" title=\"diagnostic image 3\">",
"      Severe tricuspid regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/53/1876\" title=\"diagnostic image 4\">",
"      Inferior vena cava flow TR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/62/3040\" title=\"diagnostic image 5\">",
"      Color Doppler severe TR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/46/43759\" title=\"diagnostic image 6\">",
"      Contrast enhancement CW Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/25/17823\" title=\"diagnostic image 7\">",
"      Apical 4 chamber TV prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/45/36566\" title=\"diagnostic image 8\">",
"      Apical 4 chamber echo endocarditis tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/5/16465\" title=\"diagnostic image 9\">",
"      Echocardiogram Ebstein II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/29/10705\" title=\"diagnostic image 10\">",
"      Echocardiogram apical 4-chamber Ebsteins anomaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5292|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/31/22000\" title=\"figure 1\">",
"      Doppler tricuspid regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/41/20114\" title=\"figure 2\">",
"      Echocardiogram Ebstein I",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5292|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?1/18/1315\" title=\"movie 1\">",
"      Tricuspid valve rupture 2-D echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?9/28/9679\" title=\"movie 2\">",
"      Tricuspid regurgitation subcostal echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?10/34/10799\" title=\"movie 3\">",
"      TR subcostal with color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?2/25/2448\" title=\"movie 4\">",
"      Apical 4 chamber echocardiogram with color Doppler TR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?9/1/9232\" title=\"movie 5\">",
"      TR four chamber color Doppler echo 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?24/55/25459\" title=\"movie 6\">",
"      TR and stenosis four chamber color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?7/41/7829\" title=\"movie 7\">",
"      TR four chamber color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?22/46/23279\" title=\"movie 8\">",
"      TEE 4 chamber view tricuspid valve vegetation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?0/29/466\" title=\"movie 9\">",
"      Apical 4 chamber echo tricuspid valve vegetation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?18/59/19381\" title=\"movie 10\">",
"      Echocardiogram apical 4-chamber TV carcinoid heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5292|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/43/43709\" title=\"table 1\">",
"      Hemodynamic values of normal recumbent adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=related_link\">",
"      Clinical features and diagnosis of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=related_link\">",
"      Ebstein's anomaly of the tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=related_link\">",
"      Echocardiographic evaluation of the mitral valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27766?source=related_link\">",
"      Echocardiographic evaluation of the right ventricle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/9/149?source=related_link\">",
"      Etiology, clinical features, and evaluation of tricuspid regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=related_link\">",
"      Hemodynamics of valvular disorders as measured by cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=related_link\">",
"      Ischemic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2648?source=related_link\">",
"      Nonarrhythmic complications of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8506?source=related_link\">",
"      Pathophysiology and clinical features of isolated ventricular septal defects in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15365?source=related_link\">",
"      Principles of Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=related_link\">",
"      Rhythm control versus rate control in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=related_link\">",
"      Role of echocardiography in infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5558?source=related_link\">",
"      Tricuspid stenosis: Clinical features, diagnosis, and percutaneous tricuspid balloon valvotomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_2_14379="Assessing menstrual blood loss";
var content_f14_2_14379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Questions to ask to help quantify blood loss during menses",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        How often do you change your sanitary pad/tampon during peak flow days?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How many pads/tampons do you use over a single menstrual period?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do you need to change the pad/tampon during the night?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How large are any clots that are passed?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Has a medical provider told you that you are anemic?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Women with a normal volume of menstrual blood loss tend to:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        change pads/tampons at &ge;3 hour intervals,",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        use fewer than 21 pads/tampons per cycle,",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        seldom need to change the pad/tampon during the night,",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        have clots less than 1 inch in diameter,",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        not be anemic",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Warner, PE, Critchley, HD, Lumsden, MA, et al. Am J Obstet Gynecol 2004; 190:1216.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_2_14379=[""].join("\n");
var outline_f14_2_14379=null;
var title_f14_2_14380="Clin features diaper derm";
var content_f14_2_14380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features in the differential diagnosis of diaper dermatitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Etiology",
"      </td>",
"      <td class=\"subtitle1\">",
"       Clinical features",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Irritant",
"      </td>",
"      <td>",
"       Lesions range from erythema to painful scaling papules and superficial erosions on convex surfaces in direct contact with the diaper; typically spares skin folds",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Jacquet's diaper dermatitis",
"      </td>",
"      <td>",
"       Well-demarcated papules and erosions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Granuloma gluteal infantum",
"      </td>",
"      <td>",
"       Reddish-purple nodules in inguinal folds, scrotum, buttocks, and medial thighs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Candidal",
"      </td>",
"      <td>",
"       Beefy red plaques, satellite papules, superficial pustules in skin folds but may also affect convex surfaces",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Allergic contact",
"      </td>",
"      <td>",
"       Well-demarcated erythema, scaly papules and plaques in a characteristic pattern (eg, \"cowboy holster\" or in the distribution of diaper dye); pruritic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Seborrhea",
"      </td>",
"      <td>",
"       Well-circumscribed erythematous papules and plaques with greasy yellow scale most prominent in the skin folds; rarely isolated to diaper area",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Impetigo",
"      </td>",
"      <td>",
"       Pustules that rupture, leaving a collarette of scale; honey-colored crusted erosions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Group A streptococcus",
"      </td>",
"      <td>",
"       Bright red sharply demarcated perianal or perineal rash",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Psoriasis",
"      </td>",
"      <td>",
"       Sharply demarcated erythematous scaly papules and plaques; scale may be absent in diaper area; possible family history of psoriasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Langerhans cell histiocytosis",
"      </td>",
"      <td>",
"       Red-orange or yellow-brown scaly papules, erosions, or petechiae in the groin, intertriginous regions, and scalp; may have systemic involvement",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Scabies",
"      </td>",
"      <td>",
"       Erythematous papules, nodules, and excoriations; pruritus; other family members often affected",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Congenital syphilis",
"      </td>",
"      <td>",
"       Copper-colored scaly macules and papules or moist erosions in diaper area and/or around the mouth and nose",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_2_14380=[""].join("\n");
var outline_f14_2_14380=null;
var title_f14_2_14381="MAP chemo osteosarcoma";
var content_f14_2_14381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Doxorubicin, cisplatin, and high-dose methotrexate (MAP) followed by surgery and MAP for nonmetastatic osteosarcoma (control arm, COG AOST 0331)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Agents",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Induction MAP (weeks 1 through 10)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        1, 6",
"       </td>",
"       <td>",
"        Doxorubicin",
"       </td>",
"       <td>",
"        37.5 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day by continuous IV infusion or IV push",
"       </td>",
"       <td rowspan=\"2\">",
"        1 and 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cisplatin",
"       </td>",
"       <td>",
"        60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day IV over four hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        4, 5, 9, 10",
"       </td>",
"       <td>",
"        High-dose methotrexate",
"       </td>",
"       <td>",
"        12 grams/m",
"        <sup>",
"         2",
"        </sup>",
"        IV over four hours*",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leucovorin rescue",
"       </td>",
"       <td>",
"        15 mg (approximately 10 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        ) every six hours IV or orally for 10 doses&bull;",
"       </td>",
"       <td>",
"        Starting 24 hours after beginning high-dose methotrexate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Surgery (week 11)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        11",
"       </td>",
"       <td colspan=\"3\">",
"        Resection or amputation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Postoperative MAP (weeks 12 through 29)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        12, 17",
"       </td>",
"       <td>",
"        Doxorubicin&Delta;",
"       </td>",
"       <td>",
"        37.5 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day by continuous IV&nbsp;infusion or IV push",
"       </td>",
"       <td rowspan=\"3\">",
"        1 and 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cisplatin",
"       </td>",
"       <td>",
"        60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day IV over four hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        22, 26",
"       </td>",
"       <td>",
"        Doxorubicin&Delta;",
"       </td>",
"       <td>",
"        37.5 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day IV over 24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        15, 16, 20, 21, 24, 25, 28, 29",
"       </td>",
"       <td>",
"        High-dose methotrexate",
"       </td>",
"       <td>",
"        12 grams/m",
"        <sup>",
"         2",
"        </sup>",
"        IV over four hours",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leucovorin rescue",
"       </td>",
"       <td>",
"        15 mg (approximately 10 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        ) every six hours IV or orally for 10 doses",
"       </td>",
"       <td>",
"        Starting 24 hours after beginning high-dose methotrexate",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Some pediatric oncologists limit the methotrexate dose to 20 grams total (Meyers, PA, et al. J Clin Oncol 2005; 23:2004).",
"     <br>",
"      &bull;&nbsp;Leucovorin doses adjusted depending on blood methotrexate levels.",
"      <br>",
"       &Delta; Dexrazoxane can be given with doxorubicin, although osteosarcoma-specific data are not available.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Created with data from:",
"     <br>",
"      <ol>",
"       <li>",
"        National Cancer Institute Clinical Trials. Phase III randomized study of neoadjuvant induction therapy comprising doxorubicin, cisplatin, and high-dose methotrexate (MAP) followed by surgery and adjuvant maintenance therapy comprising map alone versus map and peg-interferon alfa-2b or MAP combined with ifosfamide and etoposide in patients with resectable high-grade osteosarcoma; available at:&nbsp;",
"        <a href=\"file://www.cancer.gov/clinicaltrials/search/view?cdrid=438714&amp;version=HealthProfessional\" style=\"FONT-STYLE: italic\">",
"         file://www.cancer.gov/clinicaltrials/search/view?cdrid=438714&amp;version=HealthProfessional",
"        </a>",
"        (accessed June 15, 2012).",
"       </li>",
"       <li>",
"        Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 2003; 21:1574.",
"       </li>",
"       <li>",
"        Geller DS, Goorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 2010; 8:705.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_2_14381=[""].join("\n");
var outline_f14_2_14381=null;
var title_f14_2_14382="Bleomycin etoposide and cisplatin regimen";
var content_f14_2_14382=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bleomycin, etoposide, and cisplatin (BEP) chemotherapy for germ cell tumors",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        <p>",
"         Cycle length: 21 days.",
"        </p>",
"        Total cycles: 3 to 4*.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Bleomycin",
"        </strong>",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        30 units",
"        <sup>",
"         &loz;",
"        </sup>",
"        IV per dose",
"       </td>",
"       <td>",
"        Dilute in 50 mL normal saline (NS) and administer over 10 minutes.",
"       </td>",
"       <td>",
"        Days 1, 8, and 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Etoposide",
"        </strong>",
"       </td>",
"       <td>",
"        100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV per day",
"       </td>",
"       <td>",
"        Dilute in 500 mL NS (concentration less than 0.4 mg/mL) and administer over one hour.",
"       </td>",
"       <td>",
"        Days 1 through 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cisplatin",
"        </strong>",
"       </td>",
"       <td>",
"        20 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV per day",
"       </td>",
"       <td>",
"        Dilute in 250 mL NS and administer over two hours. Do not administer with aluminum needles or intravenous sets.",
"       </td>",
"       <td>",
"        Days 1 through 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        Induction of diuresis using at least 2000 mL of NS minimizes the risk of cisplatin nephrotoxicity. Fluid administration should be adequate to establish a urine flow of at least 100 mL/hour for two hours prior to and two hours after cisplatin administration. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        HIGH (&gt;90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Bleomycin, etoposide, and cisplatin are classified as irritants. Cisplatin can cause significant tissue damage; avoid extravasation",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with granulocyte colony stimulating factors (G-CSF) is not indicated. Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for preexisting baseline liver or renal dysfunction:",
"        </strong>",
"        Bleomycin should not be administer in patients with a baseline creatinine &gt;2.0 mg/dL. A lower initial dose of cisplatin or etoposide may be needed for patients with renal or hepatic dysfunction",
"        <sup>",
"         [2,3]",
"        </sup>",
"        . Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Basic metabolic panel (creatinine and electrolytes) prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Liver function tests prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Pulmonary function tests, as needed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Each cycle should begin on schedule regardless of the degree of myelosuppression",
"        <sup>",
"         [1]",
"        </sup>",
"        . If febrile neutropenia or thrombocytopenic bleeding occurs, a dose reduction of 25 percent for etoposide should be used for subsequent cycles. If neutrophil count remains less than or equal to 2500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        or platelets remain less than or equal to 100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        , G-CSF should be administered. Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Pulmonary toxicity:",
"        </strong>",
"        Bleomycin can be associated with the development of life-threatening pulmonary toxicity. Bleomycin should be discontinued in patients demonstrating clinical or radiographic evidence of pulmonary injury or significant deterioration of pulmonary diffusion capacity",
"        <sup>",
"         [4]",
"        </sup>",
"        . Do not reintroduce bleomycin to patients with any bleomycin-induced lung injury. Refer to UpToDate topic on \"Bleomycin-induced lung injury\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurologic toxicity:",
"        </strong>",
"        Neuropathy usually is seen after cumulative doses of cisplatin beyond 400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. Peripheral neuropathies can occur with prolonged courses (four to seven months) of cisplatin. Cisplatin treatment should be discontinued with the first signs and symptoms of the development of neurotoxicity",
"        <sup>",
"         [2,5]",
"        </sup>",
"        . Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Renal toxicity:",
"        </strong>",
"        Treatment in the setting of renal impairment (ie, creatinine &gt;2.0 mg/dL or GFR &lt;50 mL/min) requires a balanced discussion of the goals of treatment and the risks of cisplatin nephrotoxiciy in the face of impaired renal function.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count; GFR: glomerular filtration rate.",
"     <br/>",
"     * The precise number of cycles depends on the stage of the germ cell tumor.",
"     <br/>",
"     &Delta; Cumulative lifetime dose of bleomycin should be limited to 400 units because of the increased rates of pulmonary toxicity. Refer to UpToDate topic on \"Bleomycin-induced lung injury\".",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     1 unit = 1 mg.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Nichols CR, et al. J Clin Oncol 1998; 16:1287.",
"      </li>",
"      <li>",
"       Platinol (cisplatin) injection, powder, lyophilized, for solution. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 8, 2011).",
"      </li>",
"      <li>",
"       Toposar (etoposide) injection. US FDA-approved package insert US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 9, 2011).",
"      </li>",
"      <li>",
"       Blenoxane (bleomycin sulfate) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 8, 2011).",
"      </li>",
"      <li>",
"       Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2011; 29:4189.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_2_14382=[""].join("\n");
var outline_f14_2_14382=null;
var title_f14_2_14383="Esophageal perf sclerotherapy";
var content_f14_2_14383=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal perforation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 241px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This barium swallow study was performed in a 45-year old man who presented with severe chest pain following sclerotherapy for esophageal varicies. The study demonstrates two large perforations (arrows) arising from the distal esophagus (E).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_2_14383=[""].join("\n");
var outline_f14_2_14383=null;
